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Chapter 1
General clinical, morphological, biological and molecular aspects of
cholesteatoma.
Clinical aspects
Cholesteatoma is a benign, gradually expanding destructive epithelial lesion of
the temporal bone. Several hypotheses for the pathogenesis of human
cholesteatoma have been proposed of which the most important are1:
• The congenital hypothesis: cholesteatoma originates from embryological
ectoderm remnants in the petrous bone. This implies that cholesteatoma
develop behind an intact tympanic membrane in patients without a history of
aural infections.
• The metaplastic hypothesis: metaplastic changes of differentiated middle ear
epithelium lead to the formation of a cornified cholesteatoma epithelium.
• Epidermal hypotheses: cholesteatoma is considered to be an intrusion of
epithelium from the existing epidermal lining of the tympanic membrane or
external auditory canal (ME) into the middle ear cleft, forming a pathological
collision between keratinocytes and mucosa. This ME may invade into the
middle ear by 1) invagination of the tympanic membrane (retraction
hypothesis), 2) ingrowth over the edges of a tympanic membrane perforation
(migration hypothesis) and 3) medial proliferation of the basal cells through
an intact tympanic membrane (proliferation hypothesis). These epidermal
hypotheses suppose a considerable migratory capacity of the cells of the
external ear canal. In cholesteatoma genesis, a combination of these epidermal
hypotheses seems plausible. This has indeed been proposed for the retraction-
and proliferation hypotheses2.
In this thesis acquired cholesteatoma will be investigated. The genesis of acquired
cholesteatoma is based on the epidermal hypothesis. Acquired cholesteatoma will
usually occur in combination with a chronic middle ear inflammation or infection.
Clinical sequela may include destruction of the middle ear ossicles and other
structures. When untreated, there is a risk of labyrinth involvement, which may
result in vertigo and sensorineural hearing loss. Facial nerve dysfunction and
intracranial injury, although rarely seen today, are serious complications3. Early
detection of cholesteatoma is important but complicated, because the early
symptoms are difficult to distinguish from chronic otitis without cholesteatoma.
High-resolution computed tomography and magnetic resonance imaging may
facilitate pre-operative identification of cholesteatoma, although surgical exploration
remains the most effective way3,4.
Histomorphological aspects
The epithelial compartment
The epithelium of cholesteatoma exhibits generally exhibits a heterogeneous
thickness, with a majority of hypertrophic areas, adjacent to normal ones (Fig1A).
The hypertrophic area is at least 3-5 times thicker than normal retro-auricular
skin. This increased thickness is often not only due to the hypertrophic character
of the epidermis but also to an increased number of cell layers. Focal




hyperproliferation is present but not restricted to the hypertrophic layers. In the
hypertrophic layers a modification of keratinocyte morphology is often observed.
Different keratinocytes exhibit a rounded shape with hypertrophic cytoplasm and
a round nucleus. There are also keratinocytes with a spindle shape which are
oriented towards the stratum corneum with elongated cytoplasm and an oval
nucleus. The diameter of the hypertrophic cells is about twice the diameter of
normal cells.  The hypertrophic areas often show a significant widening of the
intercellular space, which suggests alterations in the network of intercellular junction
proteins. In the non-hypertrophic areas abnormally small keratinocytes are often
present, with a polygonal shape and similar to that observed in the basal layer of
the normal retro- auricular epidermis (Fig.1B). The cholesteatoma epithelium has
parakeratotic features, which is defined by the presence of nucleated cells in the
stratum corneum. Hyperkeratinization is a common phenomenon in cholesteatoma
tissue. There is a generalized inflammatory reaction with infiltration of different
types of inflammatory cells into the epithelial compartment. Clusters of
polymorphonuclear granulocytes (PMNs) and macrophages are present in areas
Fig.1 HE staining of a cholesteatoma. Original magnification: 200 x. Figure 1A represents a
hypertrophic area with round and spindle cells. Figure 1B represents a non-hypertrophic
area with very small cells.
adjacent to the stratum corneum
The subepithelial compartment
Basal membrane
Cholesteatoma basal membrane differs from that of normal skin. It is often disrupted
in areas where inflammation is present. Immunohistochemical investigation reveals
aberrant collagen 4 and laminin expression5. At the ultrastructural level, protrusions,
duplications, thickening and disruptions of the lamina densa of the basement
membrane were observed5.
The dermis
Epithelial papillary outgrowth is a common phenomenon. The dermis is hyalinized
and shows disorganized supporting fibres such as collagens and elastin.
Vascularization is two-fold when compared to normal skin6. Inflammation is often
prominently present with abundant inflammatory cells including T-cells,




macrophages, lymphocytes, mast cells and PMNs.
Biological aspects.
Is cholesteatoma a skin disease?
The presence of keratinising stratified squamous epithelium within the middle ear
cleft has led to the assumption that cholesteatoma epithelium may be classified
as a skin disease. Its parakeratotic aspect may subclassify it into the group of skin
diseases such as psoriasis, dermatitis, pityriasis lichenoides, or precancerous and
malignant squamous lesions7.
Is cholesteatoma a malignancy?
It has been suggested that several morphological aspects of human cholesteatoma
resemble those in pre-malignant and malignant skin diseases8.  These aspects
include: increased proliferation, atypical differentiation and chromosomal
abberations. However, cholesteatoma is not a malignancy because it is not invasive
and metastases have never been demonstrated. We determined the expressions
of proliferation and differentiation markers of cholesteatoma and compared these
with the results of other studies of cholesteatoma, malignant, pre-malignant and
benign skin diseases9-40. We focussed on the immunohistochemical detection of
the proliferation markers Ki-67 and PCNA, the suppressor gene p53 and the marker
of differentiation involucrin. The results are shown in Table 1.
This table shows the tendency of malignant skin diseases to be hyperproliferative.
Benign skin diseases often show increased differentiation41. When compared with
normal skin, differentiation of cholesteatoma epithelium is increased but this should
de facto be considered as evidence in favor of the benign character of the disease.
It has been argued that proliferation in cholesteatoma epithelium is increased6.
Compared with all skin diseases including benign tumours, however, the average
proliferation rate is not increased. Albino et al., who found only a marginally
statistically significant difference in proliferation between cholesteatoma and retro-
auricular skin8, has previously discussed this. Investigation of the (increased)
Table 1. represents differential expression of the proliferation markers (Ki67, PCNA), p53 and
a terminal differentiation marker (involucrin). The numbers refer to different
immunohistochemical studies of malignant-, pre-malignant-, benign skin diseases,
cholesteatoma and normal skin.




proliferative rate of cholesteatoma keratinocytes in children led to the speculation
that high cholesteatomal proliferation might be considered as an indication for
aggressive (i.e. fast growing) clinical behavior42,43. This view is not supported by
other studies, which showed that clinically less aggressive cholesteatomas also
have a high proliferation rate44. The induction of proliferative cells in suprabasal
layers of the cholesteatoma epidermis might imply a potential idiopathic response
to external stimuli in the form of cytokines released by infiltrating inflammatory
cells.
Ki-67 is expressed throughout all phases in the cell cycle and PCNA in the S-phase
but, interestingly, in cholesteatoma epithelium PCNA expression levels are higher
than those of Ki-67. It has been demonstrated that PCNA is not only associated
with delta DNA polymerase but also with mismatch repair genes45. We therefore
hypothesize that in cholesteatoma, as a consequence of a possible DNA-damaging
effect of inflammatory stress, the expression of PCNA could be higher than that of
Ki-67.
In cholesteatoma Albino et al. have demonstrated normal diploid DNA contents.
However, other studies have reported chromosomal aberrations, such as
chromosome 8 aneuploidy and chromosome 7 triploidy46,47. In these studies,
fluorescence in situ hybridization (FISH) techniques have been used. It is of note
that chronic inflammatory stress, which is a common phenomenon in cholesteatoma
epithelium, can also induce chromosomal aneuploidy or triploidy. Kinne et al.,
using the same techniques, have described similar chromosomal aberrations for
chromosome 7 and 8 in chronic rheumatoid arthritis48. Although in cholesteatoma
no clonality studies have been done, we believe that cholesteatoma does not
show inherent genetic instability, but that the reported chromosomal aberrations
are more likely to be caused by chronic inflammatory stress.
Is cholesteatoma a defective wound healing- or an inflammatory process, or both?
Pressure-induced invaginations, morphological changes of the tympanic membrane
(TM) or even perforation of the TM result in enough damage to induce wound-
healing processes8. It has also been suggested that the juxtapositioning of two
different epithelia, epidermis and middle ear epithelium, might be regarded as a
persisting epidermal defect1.
Woundhealing in cholesteatoma
The different stages of epithelial wound healing are inflammation, proliferation
and demonstrated to be present (Table 2)35,49-70. Inflammation is illustrated by the
recruitment and activation of different inflammatory cells in the subepithelial
compartment6,8.. The proliferative phase of cholesteatoma is illustrated by focal
hyperproliferative epithelial growth centres6. Migration of the newly formed tissue
to the injured site is a characteristic of remodelling. The migratory character of
keratinocytes in cholesteatoma epithelium has been reported71 and the increased
presence of the αV integrin subunit in the epithelial/subepithelial interface may
indicate the formation of new anchoring contacts necessary for keratinocyte
motiliy72. Furthermore, it has been shown that cholesteatoma fibroblasts have a
chapter1.p65 12/5/2006, 2:38 PM11
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highly migrative phenotype73. Although features of remodelling are present in
cholesteatoma, it is considered to be defective because it remains in the
inflammatory phase8.
Recently, the presence of biofilms in cholesteatoma has been demonstrated74.
Table 2. Represents different stages of epithelial wound healing according to Freedberg (70)
and the relevant literature concerning cholesteatoma pathogenesis.
Biofilms are colonies of quiescent bacteria in a hydrated matrix of polysaccharides.
In these biofilms the bacteria are protected against noxious micro-environmental
conditions as well as high concentrations of antibiotics. Although encapsulated,
bacteria can be released from the biofilm and converted into the planktonic and
thus infective form.  The presence of biofilms in cholesteatoma may be responsible
for the chronic inflammation, caused by either the released planktonic bacteria or
by the continuous released endotoxins74 such as lipopolysaccharide (LPS).
Adherence of bacteria to epithelial surfaces can induce cellular signaling and
cytokine upregulation75. Endotoxins are able to stimulate the keratinocytes of the
middle ear epithelium to cytokine production76, which may result in recurrent
inflammation. However, this is not always the default course of events because
not every patient reacts to the same degree to endotoxins. Innate or acquired
immunological factors may account for this individual variation77. When cytokines
and growth factors from inflammatory cells and/or endotoxins are present they
may induce metaplastic changes of the epithelium78. This is in accordance with
the metaplastic hypothesis proposing metaplastic changes of the differentiated
middle ear epithelium. In contrast, to the metaplastic hypothesis however,
cholesteatoma also presents without earlier inflammation notwithstanding the fact
that it is associated with inflammation.
Whether cholesteatoma is an inflammation or a wound, why does it not heal?
Many factors can impair healing, such as systemic and local factors79. Systemic




factors may be very diverse, such as malnutrition, advanced age and diabetes. To
our knowledge, it has not been proven that cholesteatoma do not heal due to
systemic reasons. Local factors, which delay or prevent healing, include the
presence of foreign bodies, tissue maceration, ischaemia and infection. Besides
infection, which is a known phenomenon in cholesteatoma pathology, it is appealing
to consider a foreign body as an inhibiting factor for wound healing. Cholesteatoma,
which is a keratinized particle encapsulated in the middle ear, might be regarded
as a corpus alienum. An immunological reaction is obvious and inflammation may
be the consequence80,81.
Of interest is also a report in which it has been demonstrated that wound fibroblasts
generate a brisk TNF response to stimulation with LPS, while under the same
conditions, normal dermal fibroblasts did not secrete any measurable amounts of
TNF82. In cholesteatoma, the increased presence of LPS may therefore contribute
to disordered wound healing83.
In addition to systemic and local factors that impair healing, an imbalance bet-
ween proteolytic enzymes and their inhibitors, or a reduction in tissue growth
factors, seem to be of particular importance in chronic wounds. An imbalance
between proteinases and their inhibitors may induce excessive proteinase activity,
which can result in a chronic wound. Moreover, it has been suggested that growth
factors can be depleted by proteases, which may also result in non-healing84. In
cholesteatoma different reports describe the increased presence of growth factors
and proteases but their degree of activity or the presence of their inhibitors, has
hardly been investigated and needs to be further explored.
Molecular aspects
In cholesteatoma, the result of the chronic inflammatory process is the presence
of a plethora of inflammatory cytokines and growth factors, expressed by
inflammatory cells and keratinocytes. The understanding of wound-healing
mechanisms has progressed considerably in recent years85,86. However, many
questions remain, such as the considerable crosstalking in the system. Most wound
signals control more than one cell activity but cell activity may also be a response
to differential triggering87. Moreover, it is certain that growth factor and matrix
signals are not the only relevant influences. Changes of gap-junctional connections
between keratinocytes at the healing margin88 may coordinate cell proliferation
and migration. Mechanical signals such as cell stretching or altered tensions at
the wound-site may prove to be important alternative factors in wound healing.
The presence of many inflammatory signaling proteins in the more or less enclosed
area of the middle ear may result in an altered or confused signal transduction
within the cholesteatoma epithelial- and sub epithelial cells. To our knowledge,
studies on cellular signaling pathways in cholesteatoma have not been published.
The aim of this thesis is to explore the main transduction signaling pathways in
cholesteatoma. Because of the complexity of the system, this study is mainly
focussed on MAPK-, Akt- and TGF-β- signaling pathways in cholesteatoma
keratinocytes and the TGF-β-signaling in the stroma. The proteins that are involved
in these signaling pathways will be discussed in the next chapters.
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Chapter 1
Aim and outline of this thesis
The main objective of this thesis is to investigate those protein signaling pathways
in human cholesteatoma  which may be involved in different aspects of
cholesteatoma pathogenesis, such as hyperproliferation, aberrant differentiation
and extra-cellular matrix deposition.
Aim of the study
The major objective of this study is to investigate cellular signaling pathways and
the expression of different proteins in human cholesteatoma in order to answer
the following questions:
1. Is increased proliferation in cholesteatoma compensated by increased
apoptosis?
2. What are the signaling pathways that influence the proliferative activity of
the keratinocytes?
3. What is the mechanism behind increased differentiation?
4. Which are the main processes leading to extra-cellular matrix alterations?
5. Are extra-cellular matrix alterations associated with aberrant epithelial
characteristics? (Is there crosstalk between these?)
6. Can different pathogenic features of cholesteatoma be explained?
Content of the thesis
In this thesis we studied the signaling pathways in human cholesteatoma
epithelium, which are involved in cellular proliferation, terminal differentiation,
cell cycle arrest and apoptosis. We also investigated to which extent TGF-ß1, as
the key factor involved in wound healing, is involved in both cholesteatoma epithelial
and stromal cellular signaling.
Chapter 1 describes cholesteatoma from a general clinical, morphological and
biological point of view.
In chapter 2 the most important proteins involved in proliferation (Ki-67, PCNA),
differentiation (involucrin) and cell cycle arrest (p53, p21cip1/waf1) as well as the
mechanism of apoptosis and the role of active caspase 3 are reviewed. In this
chapter also the phenomenon cellular signaling is introduced including MAPK, pAKT
and TGF-ß signaling pathways.
Chapter 3 concerns the study of the expression level of different proteins involved
in proliferation, cell cycle arrest and apoptosis and their association.
Chapter 4 provides evidence for an association of the expression of p21cip1/waf1 as
a marker of cell cycle arrest and MAPK signaling.
In chapter 5 we investigated the involvement of MAPK signaling in terminal
differentiation.
Terminal differentiation of cholesteatoma epithelial cells as a survival mechanism
is presented in chapter 6.




Chapter 7 describes TGF-ß bioactivation in cholesteatoma epithelium as well as
stroma.
The general discussion and summary are presented in chapter 8.
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A comprehensive review of signaling pathways investigated in this thesis.
Cellular signaling by cytokines, growth factors and peptide hormones is generally
mediated through membrane-bound receptors, whereas smaller and more lipophilic
signaling molecules such as steroid hormones and some vitamins often signal
through nuclear receptors. General features of cytokines and growth factors are
pleiotropism and redundancy. Pleiotropism refers to the ability to act on different
cell types, which reflects that different cell types may have the same type of receptors
on their membrane surface. Redundancy refers to the property of multiple cytokines
and growth factors having the same functional effect, which can be explained by
the fact that the same receptor or receptor type can bind different cytokines or
growth factors1.
This overview will concentrate on signal transduction pathways and proteins that
regulate the balance between keratinocyte cell proliferation, survival, apoptosis
and differentiation, with a particular emphasis on the role of the mitogen-activated
protein kinase-(MAPK), PI3Kinase/ Akt-, TGFß-signaling and the p53 and p21cip1/
waf1 protein.
MAPK signaling
The classic MAPkinase cascade consists of three sequental intracellular activation
steps and is initiated upon ligand binding with the appropriate receptor. The three
MAPK routes are initiated by different stimuli through different receptors but the
architecture of the signaling cascades is in general similar. After ligand binding
usually a set of adaptors such as sonic hedgehog (Shc) and growth factor receptor-
bound protein 2 (GRB2) bind and recruit the guanine nucleotide exchange factor
(GEF) SOS to the plasma membrane in proximity to Ras to exchange the GDP for
GTP on Ras proteins (Ras, Rac, Rho), which in turn activate the first member of the
cascade: a MAPKK kinase (MAPKKK or MEKK) (Fig.1)2. A MAPKKK is a serine/
threonine kinase that phosphorylates and activates MAPK kinases (MAPKK or MEK).
Figure 1.
The classic MAPKinase cas-
cade consists of three
intracellular activation steps




activates a MAPK. There are
three MAPK pathways
downstream including Ras/
Raf/ MEK1/ ERK, Ras/ MEKK/
JNK/ SAPK and the Ras/
MEKK1/ p38 MAPKinases.
Crosstalk between different
MAPK pathways may occur.
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Subsequently, MAPKK activates a MAPK by dual phosphorylation on adjacent
threonine and tyrosine residues. All three MAPK families are activated by dual
phosphorylation on both adjacent threonine and tyrosine residues separated by a
single amino acid, forming a tripeptide sequence. The second amino acid for MAPKs
for extracellular regulated kinase (ERK)  is glutamate (Thr- Glu- Tyr), for the p38
family Glycine (Thr- Gly- Tyr) and for the c-Jun N terminal-kinase (JNK) family
Proline (Thr- Pro- Tyr)3.
Several studies describe extensive crosstalk between these cascades in which a
particular kinase in one pathway affects a kinase activity in another pathway. This
illustrates that MAPKs are a highly interdependent regulatory network in which the
cellular outcome is likely to be dependent on the balance between regulatory inputs.
Full specificity is ensured through docking interactions by kinases that recognize a
distinct site on their substrates. E.g., the JNK docking region of c-Jun recognizes
JNK and determines thereby its specific phosporylation at ser63 and ser734. Scaffold
proteins can provide an assembly site for such specialized protein interactions.
These scaffold proteins usually do not contain any intrinsic enzymatic activity but
possess a structure that enables them to recruit different factors of a specific pathway
simultaneously5. But, although scaffold proteins increase specifity of individual
signaling cascades, they act at the expense of signal amplification. Spatial localization
of signaling molecules is another device to augment specificity in signal tranduction.
E.g., MEKK1 colocalizes with elements of the cytoskeleton and cytoskeletal
rearrangements may stimulate MEKK1 activity4. Finally, the duration of the signal
can strongly influence the direction of the various pathways6. However, once
activated, the MAPK cascade enables the cell to respond to environmental changes
in a prompt and ordered fashion3.
The Ras/ Raf/ MEK1/ ERK1/2-pathway.
The classic ERK1/2 cascade may serve as a prototype of the other MAPK cascades.
It is discussed extensively here to improve the understanding of the basic principle
of MAPK signal transduction pathways. The Ras/ Raf/ MEK1/ ERK1/2 cascade is
activated in response to many mitogenic stimuli, such as EGF, PDGF, thromboxane
A2, angiotensin II, TGF, insulin, LPS, osmotic stress and adherence of monocytes
and endothelial cells.
Ras is a small guanosine tri phosphatase- (GTP-ase) that is activated through its
interaction with the Grb2- Sos (son of sevenless) complex, where Sos catalyzes
the dislocation of GDP with the subsequent formation of Ras- guanosine tri phosphate
(GTP) complex. Different Ras isoforms and mutations have been observed, which
possess varying abilities to activate downstream signaling pathways. In its GTP-
bound state, Ras recruites Raf to the membrane. The known members of the
mammalian Raf gene family are Raf-1, A-Raf and B-Raf. Raf is one of the MAPKKK
kinases and subsequently activates its downstream MAPKK, MEK1. Raf, however, is
not the only inducer of MEK1 and ERK1/2 activation. All MAPKKK family members,
with the exception of MEKK4, have the potential to activate MEK1. By contrast, Raf
is unable to activate other MAPKKs5. The ERKs are characterized in two isoforms,
ERK1 and ERK2 (ERK1/2), which are sometimes referred to as p44/42 MAP kinases.
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Because ERKs, like other MAPKs, are activated by phosphorylation, protein
phosphatases dephosphorylating MAPKs are key elements in controlling ERK1/2
activity1. The duration as well as the magnitude of the ERK1/2 signal is a critical
factor in determining the response of a certain type of cell to changes of the
extracellular environment, i.e. a transient ERK1/2 signal activates other transcription
factors than a sustained ERK1/2 activity7. In keratinocytes, a mitogenic stimulus
such as provided by growth factors results in a relatively strong, transient activation
of Raf/ ERK1/2. Then, after minutes, the signaling is downregulated. Such a transient
signaling may dictate modulation in the level of P21cip1/waf1 expression, resulting in
cell cycle progression7. It has been reported that a sustained ERK1/2 signaling
may occur independently of Ras, through a newly discovered GTP-ase, Rap1.
Convergence towards ERK1/2 activation occurs on the level of Raf. Sustained
activation may also occur through the cooperative activation of different receptors
e.g., the EGF- and the integrin receptor. It has been demonstrated in keratinocytes
that such a sustained Raf/ ERK1/2 activation, induces a persistently high level of
p21cip1/waf1 and a subsequent G1 arrest7. In the nucleus, ERKs can phosphorylate
and activate a number of transcription factors such as c- fos, Elk-1, NFκB and Jun.
Fos and Jun family members homo- or heterodimerize to an AP1 transcription
promotor complex. Dependent on the composition of the complex, differential gene
transcription and protein production occurs.
Once ERK1/2 have been activated they can also target cytoplasmic - or cytoskeletal
proteins. Cross talking between other MAPKs such as p38, but also with other
signaling pathways like the TGFβ/ SMAD and the PI3K/ Akt have been reported8-10.
By its broad spectrum activation program, the Ras/ c-Raf1/ MEK1/ ERK1/2/ MAPK
signal transduction pathway is involved in most cellular processes like proliferation,
cell cycle arrest and apoptosis.
The Ras/ MEKK1/ MEK4/ JNK/ SAPK pathway
The c-Jun N-terminal kinase (JNK) was originally identified as the UV-induced fac-
tor responsible for phosphorylation and thus activation of the transcription factor
c-Jun11. JNKs are also characterized as stress-activated protein kinases (SAPK) on
the basis of their activation in response to inhibition of protein synthesis12. Three
genes JNK1, JNK2 and JNK3 with 12 possible isoforms derived from alternative
splicing products have been described13. Environmental stress, radiation, growth
factors and endotoxins induce activation of JNK/SAPKs. Regulation of the JNK/
SAPK pathway is extremely complex and is influenced by many MAPKs. There are
e.g., 13 MAPKKs that can regulate the JNK/SAPKs. This diversity allows a wide
range of stimuli to activate this MAPK pathway14. JNK/SAPKs are considered to be
important in controling programmed cell death or apoptosis.
The Ras/ MEKK1/ MEKK6/ p38 pathway
P38 is recognized as the MAPK that is activated in response to physiologic stress,
osmotic stress, LPS and UV exposure3. The p38 MAPK family has been shown to
consist of four different isoforms, p38α, -β, -γ and –δ15. Different activation and
substrate specifity of each p38 isoform results in their different physiological
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functions. It has been shown that p38α and p38β are ubiquitously expressed, while
p38γ and p38δ are expressed in a more tissue specific manner. p38γ expression,
e.g., has not been detected in the epidermis, while p38δ plays a key role in epidermal
differentiation8.
Besides activation via the MAPK signaling cascade, the p38α, but also the JNK
kinase have been shown to be activated by the protein complex TAK1/2/ TAB1,
which is part of the interleukin-1 cytokine signaling pathway6,16. Because TAB1 has
no known catalytic activity, it appears to be an adaptor or scaffolding protein14.
This is an important observation, which indicates that inflammatory cytokines, or
other adaptor proteins, may be involved in the activation of different MAPK pathways
through one signaling module. Complex formation e.g., between two MAPKs, p38
and ERK, has also been reported, underlining the complexity of the system8. A
number of downstream targets of p38 have been demonstrated. Cytoplasmic
substrates of p38 include different protein kinases which act on the translational as
well as the transcriptional level. In the nucleus, p38 regulates the activity of a
number of transcripion factors such as ELK1, p53, NFκB and AP-15,8,17. However,
p38 is generally considered to be the MAPKinase, which is dominant in the regulation
of keratinocyte terminal differentiation via the AP-1 human involucrin promoter8,18.
pAkt signaling
Recent studies have revealed a burgeoning list of Akt/ PKB substrates implicated in
oncogenesis, nutrient metabolism, transcriptional regulation and cell survival19.
Among its pleiotrophic effects, activated Akt/ PKB is a well established survival
factor and in this chapter we will discuss the molecular mechanism of its function in
regulating cell survival particularly. In mammals, three Akt/ PKB genes have been
identified, termed Akt1/ PKBα, Akt2/ PKBβ and Akt3/ PKBγ. Akt/ PKB are the
downstream effector kinases of phosphoinositide 3 kinase (PI3K), which is activated
by growth factors via a tyrosine kinase receptor and via the G-protein-coupled
receptors (Fig.2). Following ligand binding, PI3K is recruited to the cell membrane
and activated. Then PI3K interacts with and phosphorylates
phosphatidylinositoldiphosphate (PIP2), which results in generation of
phosphatidylinositoltriphosphate (PIP3). PIP3 does not activate Akt/ PKB directly
but instead appears to recruit Akt/PKB to the plasma membrane and to alter its
conformation. This allows subsequent phosphorylation by phosphoinositide-dep-
endent kinase-1 (PDK1). The Akt/ PKB protein has two phosphorylation sites,
Thr308/309 and Ser473/474, of which Thr308/309 phosphorylation is necessary
for Akt/ PKB activation while Ser473/474 is required for maximal activity20. Activated
Akt/ PKB is then released from the membrane and translocates to both the cytosol
and the nucleus21.
Different reports have suggested that pAkt/ PKB can be activated in a PI3K-
independent way. It has been shown that cyclic adenosin mono phosphate (cAMP)
inducing agents such as prostaglandin-E1 were able to activate Akt/ PKB through
Protein Kinase A (PKA). Although the mechanism is not quite clear, it appears that
dual phosphorylation of Akt/ PKB is not required for PKA mediated pAkt/ PKB
activation. It has also been shown in vitro that Akt/ PKB can be activated by Ca2+/
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calmodulin-dependent kinases19. Moreover, it has been indicated that pAkt/ PKB
can be activated by cellular stress and heat shock proteins19. Once activated, the
control of cellular survival of Akt/ PKB occurs via direct and indirect effects on the
apoptotic pathway. These effects are: post transcriptional regulation, activation of
transcription factors and metabolic interaction.
There are numerous post-transcriptional Akt/ PKB-mediated cellular survival
mechanisms of which the most important are discussed below. One important
mechanism includes phosphorylation and de-activation of different pro-apoptotic
proteins such as the BAD protein22, caspase-923, and apoptosis- mediating
MAPKinases. Akt/ PKB also initiates indirect de-activation of pro-apoptotic proteins
such as apoptosis signal-regulating kinase (ASK1)24. Akt/ PKB-induced
phosphorylation may also comprise activation of anti-apoptotic proteins of which
murine double minute 2 (MDM2) is the most essential one25. Other mechanisms
include activation of anti-apoptotic proteins like NFκB, by binding to and
phosphorylation of their inhibitors.
BAD is a pro-apoptotic member of the BCl-2 family, phosphorylation of BAD may
occur at two critical sites, Ser112 and Ser136. Phosphorylation at each site is
sufficient for association of BAD to 14-3-3. However, full inactivation of the protein
is only induced when both serines are phosphorylated22. This synergistic
phosphorylation is driven by the MAPK signaling pathway at Ser112- and by Akt/
PKB-mediated phosphorylation on the Ser136-site22.
Caspase-9 is called a death protease and acts as one of the direct effectors of
apoptosis. Akt/ PKB-induced phosphorylation of caspase-9 has been shown to
diminish the activation of its target execution caspases23.
ASK1 is one of the MAPKKKs that interacts with and is phosphorylated by Akt/ PKB
on Ser83. This results in a decreased ASK1 mediated signaling to JNK/ SAPK and a
suppressed susceptibility to apoptosis24.
Figure 2.
Akt signaling pathway, activation of different cell-surface receptors, such as tyrosin kinase
receptors, induce production of second messengers like PIP3, phosphatidylinositol 3,4,5-
trisphosphate, that convey signals to the cytoplasm from the cell surface. PIP3 signals activates
the kinase PDK1, 3-phosphoinositide-dependent protein kinase-1, which in turn activates
the kinase Akt, also known as protein kinase B. The Akt/ PKB protein has two
phosphorylation sites, Thr308/309 and Ser473/474.
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Indirect inactivation of ASK may also prevent apoptosis. The cell growth inhibitory
activity of p21Cip1/WAF1 is strongly correlated with its nuclear localization. However,
Zhou et al. have shown that Akt/PKB phosphorylation of Thr145 in p21Cip1/WAF1 triggers
its cytoplasmic localization25. Cytoplasmic p21Cip1/WAF1 then forms a complex with
ASK1 which, indirectly, results in resistance to apoptosis26.
MDM2 is an oncoprotein localized in the cytoplasm in a complex with Akt/ PKB.
After growth factor stimulation, Akt/ PKB phosphorylates MDM2 on two residues
Ser166 and Ser 186. Then MDM2 dissociates from the complex and enters the
nucleus where it binds to p53. The MDM2-p53 complex subsequently shuttles to
the cytoplasm where p53 is targeted for ubiquitine proteasome-mediated
degradation27. Under certain circumstances like cellular stress or UV-radiation, p53
has been reported to mediate cell death. Therefore, Akt/ PKB could support cellular
survival by promoting degradation of p53.
It has been shown that Akt can activate the transcription factor NF-κB and that this
blocks apoptosis induced by certain stimuli. The mechanism whereby Akt activates
NF-κB has been controversial, with evidence supporting induction of nuclear
translocation of NF-κB via activation of IκB kinase activity and/or the stimulation of
the transcription function of NF-κB28-31. It has also been demonstrated that Akt
targets the transactivation function of NF-κB in a manner that is dependent on
IκB kinase  activity and on the MAPK p3832. These disparate observations point
to deficiencies in the understanding of the Akt/ PKB-mediated NF-κB activation.
However, it is generally accepted that Akt/ PKB is involved in NF-κB transcription
of pro-survival proteins, such as Bcl-xL and caspase inhibitors19.
Recent studies have shown that Akt/ PKB can regulate cellular survival through
transcriptional factors that are responsible for pro- as well as anti-apoptotic genes.
The most known are Forkhead (FH). Akt/ PKB can directly phosphorylate all four
isoforms of FH. The phosphorylated FH proteins can promote cell survival by
inhibiting the activity of a number of FH target genes. These target genes are
usually extracellular ligands and important in promoting apoptosis. The most
common are the FAS-ligand, TNF-related apoptosis-inducing ligand (TRAIL) and
TNF receptor type 1 associated death domain (TRADD)33.
A major physiologic function of Akt/ PKB is the regulation of cell metabolism. When
high levels of insulin are present, Akt/ PKB phosphorylates glycogen synthase 3
(GSK-3), which inhibits its function. This promotes the storage and utilization of
glucose. It has been hypothesized that the inhibition of GSK3 is protective against
growth factor-deprived apoptosis21.
TGFβ signaling
Transforming growth factor β (TGFβ) is the prototype of a large family of cytokines
that regulate a wide variety of cellular processes including cell proliferation, cell
differentiation, cell motility and extracellular matrix production. The TGFβ family
includes a large number of related proteins including bone morphogenetic proteins
(BMP). The effects of TGFβ on cell growth control are complex and can vary
dramatically depending on the target cell type and the presence of other growth
factors34. TGFβ-related factors signal through ligand binding to the type II TGFβ
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receptor and, after forming a heterodimer with the type I TGFβ receptor, signal
propagation occurs by phosphorylation of the receptor-specific (R) Smads (Fig.3).
The TGFβ part of the family mediates signaling by activation of the R-Smads, Smad2
and Smad3. BMP signals through activation of the other R-Smads: Smad1, Smad5
and Smad835. The phosphorylated R-Smads then oligomerise with the common-
mediator Smad (co-Smad, Smad4), translocate to the nucleus and regulate the
transcription of target genes36. The inhibitor Smads (I-Smads), Smad6 and Smad7
function as broad spectrum intracellular antagonists of TGFβ family signaling37.
Expression of inhibitory Smads is induced by multiple stimuli, including EGF and
various members of the TGFβ family.  I-Smads bind to the activated receptor com-
plex, in competition with the R-Smads. In addition, Smad7 mediates docking of the
ubiquitine ligases Smurf1 and Smurf2 to the TGFβ and BMP receptors. This causes
ubiquitination and proteasomal degradation of the receptors. Smad7 counters most
of the TGFβ-regulated processes in the cell like growth inhibition via p21Cip1/Waf1 and
production of extracellular matrix proteins. Contradictory, Smad7 expression is
necessary for TGFβ-induced apoptosis38. The association of the Smad complexes
with transcription factors and transcriptional co-activators/co-repressors in the
nucleus regulates transcriptional control by TGFβ. TGFβ modulates several other
signaling pathways such as the JNK MAPK, which can either be activated or inhibited
by TGFβ39. Differential activation of ERK1/2 and p38 by TGFβ has also been reported
39,40. Moreover, in keratinocytes, epidermal mesenchymal transition (EMT) is induced
by TGFβ 1 through the activation of both  ERK1/2 and p38 MAPKs41. Interestingly,
co-treatment of cells with EGF enhanced the activation of these MAPKs41. In this
report, phosphorylation of JNK could not be detected. However, specific inhibitors
of MEK1, p38 and JNK all blocked EMT, indicating that activation of all three pathways
Figure 3.
TGFβ-related factors signal through
ligand binding to the type II TGFβ
receptor and, after forming a heterodimer
with the type I TGFβ receptor, signal
propagation occurs by phosphorylation
of the receptor-specific (R) Smads. The
TGFβ part of the family mediates
signaling by activation of the R-Smads,
Smad2 and Smad3. The phosphorylated
R-Smads then oligomerise Smad4 and
translocate to the nucleus, where they
regulate the transcription of target genes.
The inhibitor Smads (I-Smads), Smad6
and Smad7, function as a broad spec-
trum intracellular antagonists of TGFβ
family signaling. I-Smads bind to the
activated receptor complex, in
competition with the R-Smads. In
addition, Smad7 mediates docking of the
ubiquitine ligases Smurf1 and Smurf2 to
the TGFβ receptor. This causes
ubiquitination and proteasomal
degradation of the receptor.
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was required for TGFβ 1-induced EMT41. Crosstalking to the PI3K-Akt pathway has
also been reported. It has been demonstrated that TGFß phosphorylates Akt in a
PI3K-dependent manner, leading to TGFβ-mediated EMT and cell motility42.
p53 in repair
Activation of p53
The p53 tumour suppressor protein plays a pivotal role in essential cellular processes
like apoptosis, cell cycle control, senescence, differentiation and neoplastic
transformation. The function of p53 involves mainly the prevention of the
accumulation of genetic alterations by initiating signaling pathways to either DNA
repair by growth arrest/ senescence or by eliminating cells by apoptosis. The p53
gene can be activated in many stress responses like DNA damage, illegitimate
activation of oncogenes, hypoxia and inflammatory cytokines triggering43. In the
absence of cellular stress p53 expression is maintained at a low level. At present,
multiple lines of evidence indicate that one of the key mechanisms by which p53
functions is regulated through control of the MDM2 protein. MDM2 has been shown
to inhibit p53 activity in at least two distinct molecular mechanisms. This may
occur by binding to the N-terminal transactivation domain of p53, which blocks
interactions with other proteins necessary for p53-dependent regulation of gene
expression43. Another mechanism, essential under non-stress conditions, is the
targeting of p53 for ubiquitination which leads to proteasomal degradation45,46.
Since p53 can also associate to p53 binding sites within the MDM2 promoter, it can
trigger MDM2 expression. This is an important negative autoregulatory feedback
mechanism in p53-MDM2 interaction43,44. In some cancer cells, mutant p53 does
not induce MDM2 gene expression. In that situation, mutant p53 is not degraded
and its half-life in cells is prolonged47. The regulation of p53 stability is a complex
process that is dependent of many different forms of stress. Many pathways can be
used to allow stabilization of p53, such as phosphorylation, inhibition of MDM2
synthesis or cytoplasmic sequestration of p5345,48. Another important regulatory
mechanism of p53 stabilization via MDM2 inhibition is the binding of the alternative
reading frame (ARF). This binding inhibits the p53- targeting for ubiquitination49-51.
The consequence of ARF expression is the efficient stabilization and activation of
p53. ARF plays an important role in the induction of p53 in response to oncogenic
activation, eliminating cells with proliferative abnormalities43. In addition to the
inhibition of MDM2 by ARF, it has recently been established that the AKT/PKB kinase
can also be engaged in MDM2 inhibition (see Akt section). There are also MDM2-
independent mechanisms for p53 degradation, of which JNK, by targeting p53 for
ubiquitination, appears to be the most important52 .
Activation by p53
The molecular basis for the differential activation of particular sets of target genes
by p53 is not fully understood. Multiple molecular mechanisms most certainly
contribute to p53 target gene selectivity.  Studied intensively is the covalent
modification of the p53 protein by phosphorylation. The most important kinases
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involved in p53 phosphorylation include casein kinase, CHK1 and 2, DNA-depend-
ent protein kinase (DNA-PK) and JNK53-55. These kinases also phosphorylate MDM2
in vitro, suggesting a regulatory role for these modifications56-58. It has been
suggested that the phosphorylated p53 protein undergoes some conformational
changes, which alters its DNA-binding specifity. In line with this, it has been
demonstrated that phosphorylation on specific residues of p53 alters its DNA bin-
ding preference in vitro43. But, the in vivo relevance of this finding has been
questioned43. Besides modifications of the p53 protein, the transcription of particular
target genes appears to be determined by interaction of p53 with other proteins.
These proteins may be  transcriptional coactivators like p300, CBP, PCAF and E2F1
which have been shown to enhance p53-mediated transcription59. The need for
additional p53 partners may be of particular importance for genes with a low-
affinity p53 binding site (p53BS). It is of interest that many, if not all, pro-apoptotic
p53 target genes harbour p53BS of rather low binding affinity. Thus, this subclass
of genes may rely more heavily on cooperation of p53 and its co-activators, whereas
cell cycle inhibitory genes may be turned on by p53 as a default option43. The
question how p53 chooses between induction of apoptosis versus induction of a
viable growth arrest has received great attention. As it appears now, p53 is not the
only determinant that influences this choice.  The phenotype of the cell, the extra
cellular stimuli and the type of stress and its intensity are of great importance for
the direction of p53 transcriptional activities60. With respect to the phenotype,
different cell types may respond to the same apoptotic stimulus with either apoptosis,
or cell cycle arrest61. This might be due to their differential ability to induce pro-
apoptotic proteins of the Bcl-2 family, like Bax, Noxa and Puma43. It might also be
possible that the difference in apoptotic threshold is a reflection of the biology of
the cells involved. Cells with a high turnover, like T cells, must respond quickly to
death stimuli in order to limit the immunological response60. In general, activation
of p53 in normal cells results in cell- cycle arrest or senescence, whereas in
malignantly transformed cells p53 usually promotes apoptosis61. Moreover,
extracellular stimuli, such as cytokines and growth factors can protect cells from
apoptotic response to cell death stimuli or DNA damage by p53-promoted growth
arrest62.
The ability of p53 to promote apoptosis has been studied extensively and multiple
pathways have been identified. However, to what extent each pathway contributes
to the apoptotic activity of p53 remains a controversial matter. One of the most
prominent pathways is the mitochondrial pathway which is involved in the
transcription of the pro-apoptotic proteins Bax, Noxa and Puma and their transport
to the mitochondria43,63. This action promotes loss of the mitochondrial membrane
potential and cytochrome c release, which results in the formation of the
apoptosome, a holoenzyme consisting of cytochrome c, APAF1 and pro-caspase
963. Pro-caspase 9 is one of the members of a family of programmed cell death
executioner cysteine proteases, which are called caspases63. The apoptosome
promotes cleavage of pro-caspase 3 to its active form, activated caspase 3. Activated
caspase 3 is a so-called effector caspase, which cleaves the inactive part from
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caspase-activated DNAse (CAD). This is the final step in DNA degradation63.
Among the caspases, activated caspase 3 is considered to be an important
marker of ongoing apoptosis64. Another important pro-apoptotic activity of p53
implies the membrane death receptor induced pathway of apoptosis. Expression
of at least two of the death receptors FAS/APO1 and DR5/KILLER and one of the
death receptor ligands FASL, have been observed to be upregulated by p5365,66.
Activation of death receptors by their ligands (FAS by FASL and TRIAL by DR5)
results in trimerization and recruitment of intracellular adaptor molecules which
initiate the caspase cleavage cascade and apoptosis. Moreover, p53 can also
promote apoptosis by the negative regulation of the integrin-associated survival
signaling67,68. A differential role in p53-mediated apoptosis is played by the
transcription factor NF-κB. Its positive effects have been demonstrated69, but it
is also known as a mediator for expressing survival genes70.
The function of p53 in the control of cell cycle arrest appears to be primarily mediated
by genes, dominated by p21waf1/cip1, and will be discussed below. p53 can also trigger
growth arrest in a p21-independent way, by the preventing the activation of the
cyclin-dependent kinase (CDK)2/cyclin A kinase, which is required for G1/S
transition71. Another p21-independent, p53 mediated growth arrest is the induction
of 14-3-3s, and to some extent that of the GADD45 gene43,72, which both lead to a
G2 arrest43.
p21cip1/waf1 in cell cycle control
The p21cip1/waf1 protein has been shown to play an essential function in mediating
G1 arrest in response to DNA damage as well as in blocking the re-entry of G2 cells
into S phase. p21cip1/waf1 transcription is usually p53-dependent, but p53-independent
upregulation of p21cip1/waf1 has also been reported73. p21cip1/waf1 levels are also
regulated post-transcriptionally. p21cip1/waf1 is subject to proteosome-dependent
degradation. This degradation can be prevented by interactions with proteins, that
can bind to the c-terminal domain of p21cip1/waf1, i.e., the binding site of the
proteasome74. There are different proteins with this binding capability such as PCNA,
cyclins or MAPKs73,74. Increased p21cip1/waf1 expression is not necessarily linked to
growth arrest, as it also occurs when cells are growth-stimulated, e.g., after growth
factor exposure75. These apparently conflicting findings can be reconciled by the
fact that p21cip1/waf1 plays a dual function as both an inhibitor of cyclin/ CDK activity,
and a positive modulator of cyclin/ CDK complex formation and nuclear localization.
During physiological mitogenic stimulation, expression of D-type cyclins is induced
and gives rise to the formation of cyclin D/ CDK4 and cyclin D/ CDK6 complexes
(Fig. 4). These complexes are phosphorylated by cyclin activating kinase (CAK)
and become components from a tetrameric complex which consists of the cyclin D,
CDK4/6, p21cip1/waf1 and PCNA. The active cyclin D complex phosphorylates the
retinoblastoma protein (Rb). Rb is subsequently double phosphorylated by the
cyclin E/ CDK2/ p21cip1/waf1 / PCNA complex, which on its turn has been phosphorylated
by CAK. Once Rb has become hyperphosphorylated, the transcription factor E2F1
is released from inhibition by Rb and the expression of genes required for the S
phase is induced73.
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Thus, at low levels, p21cip1/waf1 functions as an assembly factor for cyclin D/ CDK4/
6/ PCNA complexes.
The induction of D-type cyclins in early G1 recruits p21cip1/waf1 into these active
complexes. By insertion into this complex, free p21cip1/waf1 is prevented from its
inhibitory effects on cyclin E/ CDK2/ PCNA, which promotes progression through
G173. Consistent with its requirement for progression through G1, p21cip1/waf1
expression level is very low in quiescent cells. High and sustained levels of p21cip1/
waf1, however, inhibit the activity of all CDKs, especially the cyclin E/ CDK2 complexes.
In contrast to cyclin E/ CDK2, p21cip1/waf1 is unable to inhibit cyclin E/ CDK4 at
equimolar amounts and may require higher stoichiometric amounts to achieve
inhibition73. The growth arresting activity of p21cip1/waf1 is consistent with its induction
during cell differentiation, in growth arrest by TGFβ and in senescent cells.
The amino-terminal domain of p21cip1/waf1 is both necessary and sufficient to inhibit
cyclin/ CDK activity in vitro and in vivo. The unique carboxy-terminal domain of
p21Cip1/waf1 associates with the proliferating nuclear antigen (PCNA), a subunit of δ
DNA polymerase. Besides involvement in the quaternary complex of cyclin/ CDK/
p21cip1/waf1 and PCNA, p21cip1/waf1 has also been shown to form a binary complex with
PCNA. This binary p21cip1/waf1-PCNA complex is capable to regulate  DNA replication
directly, without affecting DNA repair. The association of the carboxy-terminal domain
of p21cip1/waf1 with the proliferating cell nuclear antigen (PCNA) competes with the
interaction of the PCNA-δ DNA polymerase complex with DNA- metabolizing enzymes,
like (DNA cytosine-5) methyltransferase (MCMT) and FEN1(Flap endonuclease 1)74.
p21cip1/waf1 is involved in different anti-apoptotic processes. Inhibition by p21cip1/waf1
Figure 4.
The cell cycle and the involvement of different protein complexes in its progression. When
expression of D-type cyclins is induced, the formation of cyclin D/ CDK4 and cyclin D/ CDK6
complexes is initiated. After phosphorylation of these complexes by cyclin activating kinase
(CAK) they form a tetrameric complex with p21cip1/waf1 and PCNA. This complex phosphorylates
the retinoblastoma protein (Rb). Rb is subsequently double phosphorylated by the cyclin E/
CDK2/ p21cip1/waf1/ PCNA complex. This complex has also been formed after phosphorylation
by CAK. Once Rb has become hyperphosphorylated, the transcription factor E2F1 is released
from inhibition by Rb and the expression of genes required for the S phase is induced.
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of CDKs have been reported to be a necessary step to prevent apoptosis, either
upstream or downstream of caspase activation74 The possibility that the anti-
apoptotic effects of p21cip1/waf1 are due to cyclin/ CDK inhibition is supported by the
fact that similar effects can be observed with expression of CDK dominant negative
mutants. However, a second mechanism by which p21cip1/waf1 could protect cells
from apoptosis is through its effects on molecules more specifically involved in the
apoptotic process, such as caspases 8 and -10, caspase 3, SAPKs or MEKKs (ASK1)74.
Thus, the induction of p21cip1/waf1 in response to apoptotic stimuli arrests cell cycle
progression via the inhibition of CDKs, but may also help to prevent apoptosis.
The p21cip1/waf1 protein has also been shown to have a role in irreversible cell cycle
arrest: senescence, which may result from critically shortened telomeres76. Some
of these functions are at least partially exerted through activation of the p53
transcription factor. However, senescence and p21 transcriptional induction also
occur in p53-defective HaCaT (immortalized keratinocyte) cells77.
Besides the functions of p21cip1/waf1 in cell cycle control, apoptosis and senescence,
this molecule plays an unexpectedly complex role in differentiation. Different stu-
dies in which cellular differentiation has been induced e.g., by increasing cellular
calcium levels, or by interruption of cell-extracellular matrix contacts or by 12-o-
tetradecanoylophorbol-13-acetate (TPA application) have shown a concomitant
increase in p21cip1/waf1 expression78,79. However, p21cip1/waf1 null mice develop normally80,
which may indicate that other proteins such as p27, may complement p21cip1/waf1
function.
Recently, it has been reported that p21cip1/waf1 plays a key role in restricting the
number of keratinocyte stem cell populations, as well as further downstream,
determining the irreversibility of stem cell differentiation81. The interconnection of
p21cip1/waf1 and the Notch family of cell surface receptors, inserts the p21cip1/waf1 protein
in the stem cell/ transit amplifying cell regulatory mechanism82.
Additionally, endogenous Notch1 activity is required for induction of p21cip1/waf1
expression in differentiation. In fact, in mouse keratinocytes, the p21 gene is a
direct transcriptional target of Notch1 activation.
Altogether, p21cip1/waf1 can considered to be a mediator in the transition between
growth and growth arrest. This may imply that p21cip1/waf1 is likely to play an essential
role in restricting the number of keratinocytes with high growth potential.
A central question of differential signaling in a given system, is whether multiple
substrates can be activated simultaneously. Thus, several downstream signaling
pathways may function in parallel, perhaps acting as a multipathway signaling
unit. The proteins and protein signaling pathways described in this thesis may also
be subjected to such complex interactions.
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Objective- to investigate differences in cell proliferation, cell cycle arrest and
apoptosis between cholesteatoma and control skin.
Materials and Methods-  Immunohistochemical sections of 15 cholesteatoma
and 15 paired control retro-auricular skin samples were examined for Ki-67, p53,
p21 and active caspase 3 using image analysis, as well as for DNA fragmentation.
Results- The retro-auricular skin samples contained 5.7± 3.6% of Ki-67-positive
cells and showed a normal expression pattern. In the cholesteatoma epithelium
11.7± 9.5% of the cells were Ki-67-positive and these cells were dominantly
expressed in the basal and parabasal cell layers. Retro-auricular skin contained
5.8± 5.4% p53-positive cells and 1.0± 0.9% p21-positive cells. In the
cholesteatoma epithelia 17.8± 12.3% of the cells were p53-positive and 14.3±
11.6% were p21-positive. The expression of Ki-67, p53 and p21 differed significantly
between the two groups (p<0.05). In the cholesteatoma epithelium a positive
correlation was found between p53 and p21 expression (p= 0.016). Active caspase
3 positivity and DNA fragmentation were rarely seen in the cholesteatoma
epithelium.
Conclusion- Our results indicate that increased cell proliferation in cholesteatoma
epithelium is accompanied by an increase in p53 and p21 protein levels whilst
apoptosis is minimal.
Keywords: active caspase 3, apoptosis, cholesteatoma, immunohistochemistry,
Ki-67, p21, p53, terminal deoxynucleotide transferase-mediated dUTP nick-end
labeling.
Introduction
Cholesteatoma is a benign, but destructive middle ear tumor, characterized by a
hyperproliferative epithelium with progressive accumulation of keratin. Homeostatic
growth of keratinocytes depends on the controlled coordination of cell proliferation
and programmed cell death. However, in cholesteatoma this process appears to
be unbalanced. It has been shown that proliferating cells in the cholesteatoma
epithelium are dislocated1 and that the level of expression of proliferation markers
is aberrant2. Cell viability or cell death is determined by the activity of a complex
intertwined gene family of cell death stimulators and inhibitors. One of the most
important members of this family is the p53 protein. It can activate a cascade of
programmed cell death executioner cysteine proteases, known as caspases3,4.
Among these, activated caspase 3 is considered to be an important marker of
ongoing apoptosis5. Besides initiating apoptosis, p53 can also perform other
functions such as controlling the initiation of mitosis6. One part of the mechanism
by which p53 blocks cells at the G1 checkpoint involves upregulation of p21, a
cyclin-dependent kinase inhibitor7. This dual function, the regulation of either
apoptosis or cell cycle arrest, makes the role of p53 in the formation and
development of cholesteatoma of particular interest. In the literature, however,
there is controversy regarding the level of expression of p532,8,9 and the degree of
apoptosis in the cholesteatoma.9-11. There is also a difference of opinion concerning
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the degree of cell proliferation in cholesteatoma with respect to the expression of
p532,8,9. Furthermore, in cholesteatoma, studies of cell cycle arrest by means of
p21 expression have not previously been published. The present study was
instituted in order to compare the degree of cell proliferation, cell cycle arrest and
apoptosis in the cholesteatoma epithelium. For this purpose we have determined
the expression of: p53, the proliferation marker Ki-67, p21 and activated caspase
3. As a second measure of apoptosis we determined DNA fragmentation by means
of the terminal deoxynucleotide transferase-mediated dUTP nick-end labeling
(TUNEL) technique and calculated the percentage of apoptotic cells in the tissue
samples. The results obtained in cholesteatoma tissue were compared to those in
paired control samples from retro-auricular skin.
Materials and methods
Clinical and histopathological data
Cholesteatoma specimens from the pars flaccida and biopsies of retro-auricular
skin were obtained from fifteen patients, and immediately placed in phosphate
buffered saline. The Committee of Medical Ethics of the Leiden University Medical
Center approved the protocol. The specimens were prepared for histological
examination by fixation in 4% buffered formaldehyde for 20 h. and dehydration in
ethanol and were then embedded in paraffin wax.
Immunohistochemistry
Serial sections (4μm) were taken from each tissue block. The first and the last
sections were stained with hematoxylin- eosin (HE). Subsequent sections were
immunostained with either p53, p21, Ki-67 or active caspase 3 antibodies. The
penultimate section was used for in situ detection of fragmented DNA using the
TUNEL technique. Sections from the same tissue served as negative controls, i.e.
the primary antibody was omitted. The expressions of p53, p21, Ki-67 and active
caspase 3 were determined using an indirect immunoperoxidase method. Anti-
p53 (DO7), anti-p21( WAF1) and anti- Ki-67( MIB-1) were monoclonal antibodies
purchased from NeoMarkers Inc (Fremont, CA), Oncogene Research Products
(Cambridge, UK) and Immunotech (Marseilles, France), respectively. The dilutions
used were 1: 1000, 1:200 and 1: 400, respectively. The active caspase 3 (3p20)
polyclonal antibody was purchased from Promega (Madison, WI) and diluted 1:
400. Sections from coloncarcinoma (p53), sigmoid colon (p21), tonsil (Ki-67),
thymus and castrated rat prostate (active caspase 3) were used as positive controls.
To inactivate endogenous peroxidase, the deparaffinized sections were treated




 for 20 minutes. After rehydration, the sections
were subjected to microwave antigen retrieval in citrate buffer ( 0.01M, pH 6.0)
for 12 min12. The sections assigned for p21 and active caspase 3 antibody treatment
were also subjected to pepsin antigen retrieval (4% pepsin in 3mM HCl) for 5 min
at room temperature (RT).13 All sections were incubated with the primary anti-
body overnight at RT and then washed in PBS. The specimens were incubated
with appropriate biotinylated secondary antibodies for 30 min at RT, washed and
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subsequently incubated with peroxidase-conjugated streptavidin at RT for 30 min.





 and counterstained with HE for 1 min.
TUNEL staining
Fragmented DNA was monitored by means of an adapted fluorochrome/ enzyme
immunoassay, a modification of the method of Negoescu et al14. We used samples
of thymus and castrated rat prostate as positive controls. After deparaffination
and rehydration, the sections were pretreated with microwave irradiation (750W,
0.1M citrate buffer) for 1min and rapidly cooled. After washing with Tris-buffered
saline (TBS), they were incubated with blocking buffer (0.1 M Tris-HCl, 3% bovine
serum albumin and 20% newborn calf serum) for 15 min at RT. The slides were
rinsed with TBS and the specimens were incubated with labeling mixture in a
humid atmosphere at 37ºC for 60 min. The labeling mixture contained terminal
deoxynucleotidyl transferase and fluorescein-d uridine triphosphate [In Situ Cell
Death (ISCD) detection kit; Roche Diagnostics, Mannheim, Germany]. Transfer-
ring the slides to stop buffer (300mM sodiumchloride, 30 mM sodiumcitrate) for
15 min at RT terminated the reaction. After washing with TBS, incubation with
blocking buffer was repeated and the slides were then rinsed again in TBS.
Fluorescein was labeled with peroxidase-conjugated rabbit anti-fluorescein
isothiocyanate (DAKO, Glostrup, Denmark), diluted 1:50 with blocking buffer for
30 min at RT. This modification was used because pilot studies with the ISCD kit
converter revealed false positives. The sections were stained with DAB chromogen
for 1 min and counterstained with HE.
Morphometric analysis of immunohistochemical data
For each of the immunohistochemical markers studied, DAB positive staining was
quantified using an image analysis system (Leica Microsystems Imaging Solutions
Ltd., Cambridge, UK). The microscope was a Leica DMLB with a Leica DC 200
digital camera. The computer-assisted system used to determine the
immunohistochemical positive staining has been described elsewhere15. For each
section, images from at least five different areas were stored as digitized images.
For cell counting the same areas of the sections, but with various stains, were
used. The epithelial compartment was delineated on the screen and positive and
negative cells were counted automatically. In each section >1000 cells were counted
and the percentage of positive cells was determined.
Data analysis
Data are expressed as means ± SD. In order to compare the means of  paired
variables, the paired samples t-test was used, with a level of significance of p
<0.05 was performed. The Pearson two-tailed correlation test was used to calculate
possible correlations. Correlation was considered significant at the 0.05 level. The
SPSS 10 software package (SPSS, Chicago, IL) was used for the calculations.
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In 10/15 cholesteatoma samples we found inflammatory cells and newly formed
blood vessels in the connective tissue. In one tissue sample there was insufficient
perimatrix for analysis. In the retro-auricular skin sections there was no evidence
of inflammation.
Immunohistochemical staining of Ki-67
In the retro-auricular skin, the proportion of Ki-67-positive cells in the upper basal
layer ranged from 2.0% to 13.0%. The cholesteatoma epithelium showed positive
Ki-67 staining in cells of the upper basal layer and to a lesser extend in the
suprabasal layers (Fig1B). In the connective tissue some Ki-67-positive cells were
present. The proportion of Ki-67-positive nuclei in the cholesteatoma epithelium
showed large individual variations, ranging from 1.7% to 35.6%. On average,
however, the cholesteatoma samples showed a significantly increased percentage
of Ki-67-positive cells, compared to retro-auricular skin (p=0.031). The average
percentages of Ki-67-positive cells in retro-auricular skin and cholesteatoma
epithelium are summarized in Table1. The increased cell proliferation in the
cholesteatoma epithelium was not related to the presence of inflammation, as
non-inflamed cholesteatoma tissues also showed an increased Ki-67 expression.
Immunohistochemical staining of p53
The retro-auricular skin samples showed 0.8% to 19.2% p53-positive cells in the
basal layer. Most of the staining for p53 was found in the cells of the basal layer of
the cholesteatoma epithelium, with some staining in cells in the connective tissue
(Fig.1C.). The proportion of p53-positive cells in the cholesteatoma epithelium
varied greatly, ranging from 0.3% to 39.1%. The percentage of p53-positive cells
was significantly increased compared to that in retro-auricular skin (p=0.007).
The average percentages of p53-positive cells in retro-auricular skin and
cholesteatoma epithelium are listed in Table2. We found no difference in p53
expression between inflamed cholesteatoma samples and non-inflamed
cholesteatoma samples.
Table 1. Percentages of Ki-67-, P53- and P21-positive cells in control skin and cholesteatoma
epithelium.*p< 0.05; **p< 0.01 versus retro-auricular skin.
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Fig. 1 Immunohistochemical localization of p53, p21 and Ki-67 in serial sections of human
cholesteatoma epithelium: (A)HE staining; (B) Ki-67-positive cells are expressed in the basal
and suprabasal layers of the epithelium (arrowheads); (C) Many p53-positive cells are
expressed in the basal layer;(D) p21-positive cells are expressed in the lower suprabasal
layers; (E) active caspase3; (F) TUNEL staining showing a positive cell (arrowhead). Original
magnification x 200. E= epithelium; CT= connective tissue
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Immunohistochemical staining of p21
In retro-auricular skin a maximum of 2.1% of the cells were positive for p21. The
p21- positive cells of the retro-auricular skin and the cholesteatoma epithelium
were locally expressed in the lower suprabasal layers. In some cholesteatoma,
p21 expression was also observed in the connective tissue (Fig.1D). p21-positive
cells were present in the epithelium of all 15 cholesteatoma samples. The proportion
of p21-positive cells varied considerably, ranging from 0.4% to 32.5%. When
compared to retro-auricular skin, the percentage of p21-positive cells in
cholesteatoma tissue was significantly increased (p=0.001). Table 2 lists the
percentage of p21-positive cells in retro-auricular skin and cholesteatoma
epithelium. We found no difference in p21 expression between samples with or
without inflammation.
Co-expression of Ki-67, p53 and p21
Using the Pearson two-tailed correlation test, a significant positive association
was observed between p53 and p21 protein expression (p= 0.016). We did not
find a correlation between any of the other proteins.
Detection of apoptosis
Immunohistochemical staining of active caspase 3
The retro- auricular skin sometimes contained a single positive cell in the granular
layer. In the cholesteatoma epithelium samples there were hardly any active
caspase 3 positive cells (Fig.1E). In those cells that were positive for active caspase
3, the nuclei showed a fragmented morphology. The data were not used for further
calculations as all tissue samples contained a negligible number of positive cells.
TUNEL (modified method)
The retro- auricular skin cells of the granular layer were only occasionally TUNEL-
positive. The stromal portion showed a small number of TUNEL-positive cells in 10
cholesteatoma samples. In the stroma of some cholesteatoma samples a few
clusters of TUNEL-positive cells were detected, indicating an increase in apoptosis.
In some epithelia of cholesteatoma samples a single TUNEL-positive cell was
observed (Fig.1F). All TUNEL-positive cells had fragmented nuclei. The samples
showed a negligible number of TUNEL-positive cells and therefore these data were
not used for further calculations.
Discussion
This is the first report to document, in the same study, cell proliferation, cell cycle
arrest and apoptosis in cholesteatoma epithelium. In most cholesteatoma samples
we observed active inflammation, involving neutrophils, monocytes, macrophages
and newly formed blood vessels. In the epithelial layer of the cholesteatoma we
found increased expression of the proliferation marker Ki-67. Concomitantly, the
cholesteatoma epithelium showed overexpression of p53. The increased Ki-67
expression was not related to the overexpression of p53. In addition, we found a
remarkable increased proportion of p21 in the epithelial layer. We demonstrated a
significant positive correlation between p53 and p21. Apoptosis, which is determined
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by active caspase 3 expression, was not detected in the cholesteatoma epithelium.
This was confirmed by the observation that a negligible proportion of apoptotic
cells was determined using the TUNEL technique. The abundant presence of the
proliferation marker Ki-67 and the overexpression of p53 in cholesteatomal tissue
have been reported before1. High expression of p53 has also been mentioned by
others, but with a subsequent high level of apoptosis9, as determined using the
TUNEL assay. Our analyses, however, clearly demonstrate that there was no increase
in apoptosis in the cholesteatoma samples. Our study demonstrates cell
proliferation, characterized by increased Ki-67 protein expression, but also an
increase in p53 protein level, which suggests a halt to proliferation by means of G1
blockade7. These unexpected results might be caused by a dysfunctioning p53
protein. p21, however, is upregulated in cholesteatoma, indicating a transcriptionally
active p53 protein16. In addition, we have demonstrated that apoptosis in
cholesteatoma can be adequately blocked. This is only possible if there is a
combination of normal functioning p53 and p21 proteins17. Such a concept is also
supported by previous reports showing that cholesteatomas are genetically stable
and have a normal DNA content1. This indicates that, in cholesteatoma, apoptosis
may not be required as a cellular protection mechanism.
Conflicting results have been established in the cholesteatoma epithelium. The
presence of normal functioning p53 and p21 proteins suggests an effective
proliferation block. This, however, is not the case. The apparently ineffective
proliferation block might be caused by different functions of p2118. The p21 molecule
initiates the cell cycle arrest by binding to the regulators of the cell cycle, the
cyclin/cyclin-dependent kinase (CDK)  proteins. It has been demonstrated that
the CDK inhibitory function of p21 is regulated stoichiometrically, i.e. only when
p21 is in molar excess19. In the cholesteatoma epithelium, it is possible that inhibition
of CDK activity occurs in cells with a molar excess of p21. When the molar abundance
of p21 decreases, because of the short half-life of the p21 molecule20, the cell
cycle is no longer inhibited. This assumption is supported by the observation of
suprabasal expression of Ki-67 in the cholesteatoma epithelium1,2 (Fig 1B.).
The p21 protein itself, however, can act as a positive modulator of cell cycle
progression. It has recently been found that, in the presence of calcium, p21 can
bind directly to Calmodulin18. This interaction appears to be required for nuclear
localization of cyclinD/CDK421, which switches on proliferation. Most cholesteatoma
tissues exhibit a considerable bone resorption. Therefore, high local concentrations
of calcium might be present. Under these specific conditions, the p21 protein can
initiate cell proliferation in the cholesteatoma. Inflammation or the presence of
endotoxins can also trigger proliferation. We therefore assume that, in the epithelial
layer of the cholesteatoma, the Ki-67 protein is increased by means of different
signals. This is also plausible for the upregulation of the p53 protein.
Hyperproliferation can increase p53, but neutrophils can also activate the p53
protein by releasing reactive oxygen. It appears that, in cholesteatoma epithelium,
the coordination of the cell cycle has become dysfunctional. However, our results
prove that the p53 protein can effectively upregulate p21 expression as protection
against apoptosis. In this study we have demonstrated that increased proliferation
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in the cholesteatoma is not compensated by apoptosis, but may be associated
with cell  cycle arrest. Future research will focuss on the role of p21 in stem cell
commitment and differentiation in the cholesteatoma.
Acknowledgments
The authors thank Dr D.O.E. Gebhardt for critically reading the manuscript, Mrs
A. van der Wal for her expert technical assistance and Mr K. van der Ham for
help with producing the images.
References
1. Albino AP, Kimmelman CP, Parisier SC. Cholesteatoma: A Molecular and Cellular Puzzle.
Am J Otol 1998; 19: 7-19.
2. Bernal Sprekelsen M, Ebmeyer J, Buchbinder A, Sudhoff H. Comparative analysis of
the proliferative capacity of cholesteatomas. Acta Otorrinolaring Esp 2000; 51 (4):
299-307.
3. Schuler M, Green D.R. Mechanism of p53- dependent apoptosis. Biochem Soc Trans
2001: 29 (6): 684-8.
4. Hengarter MO, The biochemistry of apoptosis. Nature 2000; 407: 770-6.
5. Earnshaw W, Martins L, Kaufmann  SH. Mammalian caspases: structure, activation,
substrates and fuctioning during apoptosis. Annu Rev Biochem 1999; 68: 383-424
6. Bargonetti J, Manfredi JJ. Multiple roles of the tumour suppressor p53. Curr Op Onc
2002; 14: 86-91.
7. Vogt Sionov R, Haupt Y. The cellular response to p53: the decision between life and
death. Oncogene 1999; 18: 6145-57.
8. Motamed M, Powe D, Jones L, Kendall C, Banerjee AR. Are p53 and MIB-1 overexpressed
in cholesteatoma? Clin Otolaryngol  2000; 25: 575.
9. Choufani G, Mahillon V, Decaestecker C, et al. Determination of the levels of expression
of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating
cells to enable distiction between recurrent and noncurrent cholesteatomas. The
Laryngoscope 1999; 109: 1825-31.
10. Ergun S, Carlsöö B, Zheng X. Apoptosis in meatal skin, cholesteatoma and squamous
cell carcinoma of the ear. Clin Otolaryngol 1999; 24: 280-5.
11. Koyima H, Tanaka Y, Tanaka T, Miyazaki H, Shiwa M, Kamide Y, Moriyama H. Cell
proliferation and apoptosis in human middle ear cholesteatoma. Arch Otolaryngol
Head Neck Surg  1998; 124: 261-4.
12. Hazelbag HM, v.d. Broek LJCM, van Dorst EBL, Offerhaus JA, Fleuren GJ, Hogendoorn
PCW. Immunostaining of chain-specific keratins on formalin-fixed, paraffin-embedded
tissues: a comparison of various antigen retrieval systems using microwave heating
and proteolytic treatments. J Histochem Cytochem 1995; 43 (4): 429-37.
13. Wrone- Smith T, Bergstrom J, Quevedo ME, Reddy V, Gutierrez- Steil C, Nickoloff BJ.
Differential expression of cell survival and cell cycle regulatory proteins in cutaneous
squamoproliferative lesions. J Dermatol Science 1999; 19: 53-67.
14. Negoescu A, Lorimier P, Labat- Moleur F et al. TUNEL: Improvement and evaluation of
the method for In Situ apoptotic cell identification. Biochemica 1997; 2: 12-7.
15. Jacobs JJL, Lehé C, Cammans KDA, Yoneda K, Das PK, Elliott GR. An automatic method
for the quantification of immunostained human Langerhans cells. J Imminol Meth
2001; 247: 73-82.
16. Bukholm IK, Nesland JM, Kåresen R, Jacobsen U, Børresen AL. Relationship between
abnormal p53 protein and failure to express p21 protein in human breast carcinomas.
J Pathol 1997; 181: 140-5.
17. Huang S, Liu LN, Hosoi H, Dilling MB, Shikata T, Houghton PJ. p53/p21cip1 cooperate in
enforcing rapamycin- induced G1 arrest and determine the cellular response to
rapamycin. Cancer Research 2001; 61: 3373-81.
18. Dotto GP. p21waf1/cip1: more than a break to the cell cycle? Biochim Biophys Acta 2000;
M43-M56
19. Harper JW, Elledge SJ, Keyomarsi K et al. Inhibition of cyclin-dependent kinases by
p21. Mol Biol Cell 1995; 6: 387-400.
chapter 3.p65 12/5/2006, 2:39 PM47
48
Chapter 3
20. Rössig L, Badorff C, Holzmann Y, Zeiher AM, Dimmeler S. Glycogen synthase kinase-
3 couples AKT- dependent signalling to the regulation of p21cip1 degradation. J Biol
Chem 2002 277 (12): 9684-9.
21. Taulés M, Rodríguez- Vilarrupla A, Rius E et al. Calmodulin binds to p21cip1 and is
involved in the regulation of its nuclear localization. J Biol Chem 1999; 274(35):
24445-8.
chapter 3.p65 12/5/2006, 2:39 PM48
49
                                                                                       ERK1/2 MAPK and P21cip1/waf1
4
Sustained extracellular signal-
regulated kinase 1/2 mitogen-
activated protein kinase signalling is
related to increased p21 expression
in cholesteatoma epithelium.
Chapter 4
MARGRIET A. HUISMAN1, EMILE DE HEER2 and JAN J. GROTE1
Departments of 1Ear, Nose & Throat and 2Pathology, Leiden University Medical
Center, The Netherlands.




Conclusion. These results show for the first time that the RAS/ RAF/ ERK1/2
MAPK signalling pathway is active and involved in p21-mediated cell cycle arrest
in human cholesteatoma epithelium.
Objective. In a previous report we have demonstrated that the epithelium in
human cholesteatoma, is characterized by high p53-dependent p21 expression.
The RAS/ RAF/ extracellular signal-regulated kinase (ERK)1/2 mitogen-activated
protein kinase (MAPK) signalling pathway can induce p21 expression and
subsequent cell cycle arrest via p53-dependent or -independent mechanisms.
We designed the present study to investigate whether the RAS/ RAF/ ERK1/2
MAPK signalling pathway is involved in p53-dependent and p21-mediated cell
cycle arrest in human cholesteatoma.
Material and methods. A total of 18 cholesteatoma samples and 18 paired control
retro-auricular skin samples were immunohistochemically stained for p53, p21,
phosphorylated ERK1/2 (pERK1/2) and total ERK1/2. Positive cells were counted
by means of digital image analysis. Double-label fluorescence
immunohistochemistry was performed to demonstrate co-expression of p21 and
pERK1/2.
Results. Protein expression of p53, p21 and pERK1/2 differed significantly between
cholesteatoma epithelium and retro-auricular skin (p <0.01). In cholesteatoma,
co-expression of p21 and pERK1/2 was prominent, whereas in retro-auricular skin
there was hardly any co-expression. Positive correlations were found between
p53 and p21 (p =0.003) and between p21 and pERK1/2 ( p =0.013).
Keywords: Cell cycle arrest, cell signalling, immunohistochemistry, p53
Introduction
Cholesteatoma is a non-malignant, destructive ear disease, caused by the presence
within the middle ear cleft of keratinizing stratified squamous epithelium. Several
theories of the pathogenesis of human cholesteatoma have been described, the
most important being the migration, invasion and proliferation theory1. The link
between these theories is disruption of, or damage to, the lamina propria of the
tympanic membrane, which usually occurs in combination with a chronic middle
ear infection. The biological properties and inductive forces of the inflammation
may lead to the invasion of stratified squamous epithelium into the middle ear
cleft, causing the formation of cholesteatoma. Clinical sequela may include
destruction of the middle ear ossicles and other structures. Cholesteatoma
epithelium deviates from normal epidermis in terms of hyperplasia, aberrant
differentiation and progressive accumulation of keratins2. In human epidermis,
normal turnover of keratinocytes depends on controlled coordination between
proliferation and differentiation. This requires a regular supply of de novo
differentiated cells. It has been demonstrated that irreversible cell cycle arrest is
an early and integral part of epidermal differentiation3. A key protein involved in
cell cycle arrest is the cyclin-dependent kinase inhibitor (CDKI) p21cip1/waf1. Binding
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of the p21cip1/waf1 protein to cyclins and cyclin-dependent kinases (CDKs) prevents
transition of the cell cycle from the G1 phase to the S phase and from the G2
phase to the M phase4. P21cip1/waf1 also inhibits DNA replication by association
between the carboxy-terminal domain of p21cip1/waf1 and proliferating cell nuclear
antigen (PCNA). At least two DNA- metabolizing enzymes, i.e. Fen1 and DNA
(cytocine-5)methyltransferase, have been shown to bind to the same overlapping
region of PCNA in competition with p215. Association with cyclins, CDK, and PCNA
makes the p21 cip1/waf1 protein an essential component of cell cycle control. Expression
of p21 cip1/waf1 is usually controlled at the transcriptional level by p53-dependent
and -independent mechanisms6. The mitogen-activated protein kinase (MAPK)
pathway RAS/ RAF/extracellular signal- regulated kinase (ERK)1/2 has been
described as being both a p53-dependent and -independent mechanism of p21
induction6-9. Previously, we have demonstrated that the p21 cip1/waf1 protein
expression was increased and positively correlated with p53 expression in human
cholesteatoma epithelium, compared to normal skin10. In cholesteatoma, Huang
et al have also demonstrated an increased expression of the RAS protein11. Because
of the essential role of p21 in cell cycle control, we investigated whether the RAS/
RAF/ ERK1/2 MAPK pathway is involved in p53-dependent, p21-mediated cell cycle
arrest in human cholesteatoma epithelium. For this purpose we determined the
expression of: (i) p53, (ii) p21, (iii) phospho-activated ERK1/2 (pERK1/2) and (iv)
total ERK1/2. In addition, co-expression of pERK1/2 and p21 proteins was
investigated by means of double-label fluorescence immunohistochemistry using
confocal laser scanning microscopy. The results obtained with cholesteatoma tissue
were compared to paired control samples from retro-auricular skin.
Materials and methods
Clinical and histopathological data
Cholesteatoma specimens and biopsies of retro-auricular skin were obtained from
18 patients. The samples were placed in phosphate-buffered saline immediately
after the operation. The Committee of Medical Ethics of Leiden University Medical
Centre approved the protocol. The specimens were prepared for histological
examination by fixation in 4% buffered formaldehyde for 20 hours followed by
dehydration in ethanol and embedding in paraffin wax.
Immunohistochemistry
Sections (4-μm thick) were taken from each tissue block. The first and last sections
were stained with hematoxylin eosin. The sections were immunostained with
antibodies respectively against p53 (clone DO7), p21waf1/cip1 (clone SX118), phospho-
ERK1/2 (Thr202/Tyr204) and ERK1/2. Anti-p53 and anti-p21 were monoclonal
antibodies purchased from Dako B.V. (Glostrup, Denmark) and anti-pERK1/2 and
anti-total ERK1/2 were polyclonal antibodies obtained from Cell Signaling
Technology (Beverly, MA). The dilutions used for anti-p53 and anti-p21were 1:
100, 1: 500 and for anti-pERK1/2 and anti-total ERK1/2,1: 200 respectively. Double
staining was performed by means of immunofluorescence. Anti-p21 was conjugated
to goat anti-rabbit horseradish peroxidase (HRP; Kirkegaard & Perry Laboratories,
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Gaithersburg, MD) and labelled with Tyramid-fluorescein isothiocyanate (FITC;
1:100; kindly provided by Dr. C. van Kooten, Department of Nephrology, Leiden
University Medical Center). Anti-pERK1/2 was labelled with goat anti-rabbit Ig
conjugated to Alexa 546 (1:100; Molecular Probes, Leiden, The Netherlands).
Sections from the same tissue served as negative controls, i.e. the primary antibody
was omitted.
Expression of single proteins
Expression of p53, p21, pERK1/2 and total ERK1/2 was determined using an indirect
immunoperoxidase method. Sections from sigmoid (p21) and colon carcinoma
(p53, pERK1/2 and total ERK1/2) were used as positive controls. After
deparaffination, the sections were treated with methanol containing 0.3% hydrogen
peroxide for 20 minutes in order to inactivate endogenous peroxidase. The sections
were rehydrated and subjected to microwave antigen retrieval in boiling citrate
buffer    (0.01M, pH 6.0, for 10 min)12. All sections were washed in Tris-buffered
saline (TBS) and incubated with the primary antibody in 0.2% bovine serum albumin
(BSA) in TBS. The sections were incubated overnight at room temperature (RT)
and then washed four times in TBS. The sections used for the p21 antibody
treatment were subjected to a secondary incubation with rabbit anti-mouse in
Dako diluent buffer (1:2000) for  20 min at RT. After washing in TBS, the p21,
pERK1/2 and total ERK1/2 sections were incubated with ChemMate Envision (anti-
rabbit and anti-mouse; Dako) for 30 min at RT and developed with 3,3'-
diaminobenzidin chromogen (DAB+; 1:50; Dako), for 5 min at RT. The sections
were counterstained with hematoxylin for 1 min. The other specimens were
incubated with the appropriate biotinylated secondary antibody for 30 min at RT,
washed with TBS and subsequently incubated with peroxidase-conjugated





 for 15 min and counterstained with hematoxylin for 1 min.
Co-expression of p21 and pERK1/2




and 0.1% sodium azide for 20 min, in order to block endogenous peroxidase.
They were then rehydrated and subjected to microwave antigen retrieval in boiling
citrate buffer (0.01M, pH 6.0 for 10 min)12. After washing in TBS the sections were
incubated with both primary antibodies against p21 and pERK1/2 in 0.2% BSA in
TBS overnight at RT. They were then washed four times in TBS and incubated with
goat anti-mouse Ig-HRP and goat anti-rabbit-Alexa 546 for 30 min at RT. The
sections were subsequently incubated with Tyramid-FITC in Tris-HCl buffer (0.2 M




) for 30 min at RT. After washing
in TBS, the sections were mounted in Vectashield (Brunschwig Chemie, Amsterdam,
The Netherlands). The cross-reactive background of all reagents could be excluded
by sequential omission of individual reagents, resulting in either single labelling or
absence of labelling.
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Morphometric analysis of immunohistochemical data
For each of the immunohistochemical markers studied, DAB positive cells were
counted using an image analysis system (Leica Microsystems Imaging Solutions
Ltd. Cambridge, UK.). The microscope was a Leica DMLB with N Plan 20 x 0.4
objective and a Leica DC 200 digital camera. The computer-assisted system used
to determine the positive immunohistochemical staining has been described
elsewhere13. For each section, images from at least five different areas were stored
as digitised images. For cell counting the same areas of the sections were used ,
but with various stains. The epithelial compartment was delineated on the screen
and the positive and negative cells were counted automatically. In each section >
1000 cells were counted, and the percentage of positive cells was determined.
Confocal laser scanning microscopy was performed using a confocal laser scanning
microscope (Zeiss LSM510) in a multi-track setting. FITC was excited at 488nm
and detected using a 505-530 band-pass filter. Alexa-546 was excited at 543nm
and detected using a 560-615nm band-pass filter. Using these settings the two
fluorochromes could be detected separately without any background in the other
channels. Each fluorochrome was given an artificial colour: FITC, green; Alexa-
546, red. A PH2 Plan-NEOFluar 25 x 0.80 Imm Korr objective was used.
Data analysis
Data are expressed as mean ± SD. Because of a non-Gaussian distribution of
parameters, we used the non-parametric Wilcoxon signed rank test for comparison
of the differences between protein expression in cholesteatoma and retro-auricular
skin. The level of significance was set at p< 0.05. The Spearman’s rank correlation
test was used to calculate correlations. Correlations were considered significant at




On macroscopic inspection at surgery 11/18 cholesteatoma were considered
clinically infected. In13/18 cholesteatoma samples, microscopic inspection revealed
inflammatory cells and newly formed blood vessels in the connective tissue. In
three tissue samples there was insufficient connective tissue for analysis. In the
retro-auricular skin sections there was no evidence of inflammation.
Expression of p53, p21, pErk1/2 and total ERK1/2
Positive expression of p53 was mainly found in the cells of the basal layer but also
in the cells of the suprabasal layers of the cholesteatoma epithelium (Figure 1A).
The percentage of p53-positive cells was significantly increased compared to that
of retro-auricular skin (p = 0.003). The average percentages of p53-positive cells
in retro-auricular skin and cholesteatoma epithelium are listed in Table I. p21-
positive cells were present in the epithelium of all 20 cholesteatoma samples,.
p21-positive cells were locally expressed in the lower suprabasal layers of the
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retro-auricular skin and cholesteatoma epithelium (Figure 1B). In cholesteatoma,
p21 expression was also observed in the upper suprabasal layers. Compared to
retro-auricular skin, the percentage of p21-positive cells in cholesteatoma tissue
was significantly increased (p <0.001). Table I lists the percentages of p21-positive
cells in retro-auricular skin and cholesteatoma epithelium. Expression of pERK1/2
in cholesteatoma epithelium was mainly nuclear and localized in all layers of the
cholesteatoma epithelium. The location of total ERK1/2 in the epithelial tissue was
similar, but total ERK1/2 expression was also more cytoplasmatic (Figures 1C and
D). These observations were consistent with the expression of pERK1/2 and total
ERK1/2 in retro-auricular skin. Total ERK1/2 staining was performed as a control
of the location of pERK1/2 and for that reason the cells were not counted. On
average, cholesteatoma samples showed a significantly increased percentage of
pERK1/2-positive cells  compared to retro-auricular skin (p<0.001). The average
percentages of pErk1/2-positive cells in retro-auricular skin and cholesteatoma
epithelium are summarised in Table I.
Associations of  p53, p21 and pErk1/2 with inflammation
We investigated whether there was a correlation between the samples which were
considered clinically infected and protein expressions, but could not find no such
relationship. We also found no relationship between the presence of inflammatory
cells and protein expressions.
Associations of  p53, p21 and pErk1/2
Using  Spearman’s rank correlation test, a significant positive association was
observed between p53 protein expression and p21 (p=0.003) and between p21
protein expression and pErk1/2 (p=0.013). We found no correlation between p53
and pErk1/2.
Co-expression of p21 and pErk1/2
In cholesteatoma epithelium, confocal laser scanning microscopy revealed that
almost all cells in the basal cell layer were pERK1/2 positive. In this layer hardly
any ERK1/2 positive cell showed p21 co-expression. In the suprabasal layers co-
expression of pERK1/2 and p21 was prominent. (Figures 1E-H). In retro-auricular
skin we found almost no co-expression.
Table 1. Percentages of  P53, P21and pERK1/2-positive cells in control skin and cholesteatoma
epithelium.
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Figure 1. Immunohistochemical localization of P53, p21 and Ki-67 in serial sections of human
cholesteatoma epithelium: (A) HE staining; (B) Ki-67-positive cells are expressed in the
basal and suprabasal layers of the epithelium (arrowheads); (C) Many p53- positive cells are
expressed in the basal layer; (D) p21-positive cells are expressed in the lower suprabasal
layers; (E) active caspase3; (F) TUNEL staining showing a positive cell (arrowhead). Original
magnification x 200.




Our results show that in human cholesteatoma epithelium the RAS/ RAF/ ERK1/2
MAPK pathway is involved in p53-dependent increased expression of p21. This is
demonstrated by the correlated expression of p53 and p21 and of p21 and active
ERK1/2. It has been demonstrated that the RAS/ RAF/ ERK1/2 MAPK signalling
pathway is activated in response to many mitogens, such as growth factors,
cytokines, bacterial endotoxins, insulin and osmotic stress14. It has also been
reported that activated RAS elicits premature cell senescence (G1 arrest), which
is accompanied by increased expression of p53, p21 and p1615. Although
transcription factors are important MAPK targets, MAPK can also regulate protein
expression through post-transcriptional mechanisms16,17. Differential processes may
be of importance in this context. The process of post-transcriptional-regulated
stabilization of the p53 protein via RAF activation has been reported to result in
increased p21 expression18. Another post-transcriptional effect of activated MAPK
may be upregulation of the p21 protein by preventing of its degradation by the
26S proteasome complex17.
Curiously, in the MAPK signalling pathway, ERK1/2 activation has been associated
with both stimulation and inhibition of cell proliferation. In this context, it has
been shown in several studies that the magnitude of ERK1/2 activation determines
whether the cellular response includes the induction of p216,9,18. Thus, the induction
of p21 expression requires a stronger ERK1/2 signal than ERK1/2-mediated
induction of proliferation. It has been demonstrated that with high and sustained
ERK1/2 activity, p21 binding to the proteasome complex is inhibited18, i.e. the
proteasomal degradation of p21 is reduced, which may result in high expression
of p219,17.
Roper et al. have shown that, for proper RAS/ RAF/ ERK1/2 MAPK-induced cell
cycle arrest, both p53 as well as p21, need to be present19. Increased stability of
p53 after RAF activation may then lead to transcription of p21. Roper et al. observed
that this RAF-mediated induction of p21 is lost in P53-/- cells. This group also
reported that p53 is not induced at the RNA level after RAF activation. This may
indicate that RAF regulates p53 at the level of protein stabilization19, which has
also been confirmed by others20. Reciprocal to this, Lee et al. showed that p53 can
also mediate MAPK activation21. This may imply a positive feedback loop in which
permanent growth arrest could be augmented by sufficient upregulation of either
p53 or MAPK pathways. Moreover, Lee et al. found that p53-mediated ERK1/2
activation is higher and more sustained than that without p53 involvement21. These
reports fit well with the expression profile observed in cholesteatoma epithelium.
Increased RAS expression has previously been demonstrated in human
cholesteatoma epithelium11 and high expression of activated ERK1/2 implies an
active RAS/ RAF/ ERK1/2 MAPK signalling pathway. Furthermore, increased p53
and p21 expression was detectable in all suprabasal layers in cholesteatoma
epithelial tissue, indicating an extended lifetime of both proteins. The correlation
between p53 and p21 expression may imply a direct involvement of p53 in p21
expression. Finally, the co-expression of pERK1/2 with p21 and their correlation,
although less than that between p53 and p21, indicates that in human
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cholesteatoma pERK1/2 is also involved in the mechanism of p21 upregulation.
We speculate that, in human cholesteatoma, activation of MAPK is mainly caused
by external factors, such as inflammation-induced growth factors, cytokines and
bacterial endotoxins. These factors may also be responsible for primary upregulation
of p53 with subsequent transcription of p21. Low or intermediate concentrations
of pERK1/2 may result in progression through the cell cycle. When triggering is
prominent, e.g. as a result of different mitogenic stimuli, strong RAS/ RAF/ERK1/
2 activation may occur9. Stabilization of p53 by RAF may then induce positive
feedback to produce a sustained increased level of activated ERK1/2 (Figure 2).
The latter factor is a major condition for the prevention of p21 breakdown, which
is a prerequisite for proper cell cycle inhibition9. In cholesteatoma epithelium,
these differential processes were visualised by single pERK1/2 expression in the
proliferating compartment. In the suprabasal layers, when pERK1/2 expression
was sustained the cells were also found to be positive for p21(Figures 1E-G).
We postulate that, in cholesteatoma cell cycle arrest, posttranscriptional
mechanisms such as p53 stabilization and prevention of p21 breakdown, play
prominent roles. Prolonged MAPK-induced cell cycle inhibition causes accumulation
of epithelial cells, which are in G-phase arrest18. In human cholesteatoma, prevalent
Figure 2. Induction of p21 transcription in human
cholesteatoma epithelium. External triggers, like growth
factors initiate the activation of the MAPKinase pathway
and the transcription of different proteins involved in
proliferation. External triggers may also initiate the
production of p53. When there are different stimuli,
both the MAPKinase pathway and the production of
p53 are initiated. RAF activation may then result in
stabilisation of p53, which may lead to a further
activation of RAS and a sustained ERK1/2
phosphorylation. This prevents p21 breakdown, which
is central to an increase in p21 concentration and cell
cycle arrest
cell cycle arrest may contribute to epithelial hyperplasia.
MAPK signalling, however, is not only restricted to a special cell type, which led us
to presume that different stromal cells are also activated. The study of MAPK
signalling in all cholesteatoma cells may, in our opinion, help us in the understanding
of processes such as invasion, bone resorption, re- inflammation, etc.
Our next study will concern the specific role of the different mitogenic stimuli in
the activation of the RAS/ RAF/ ERK1/2 MAPK pathway in human cholesteatoma
epithelium.
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To investigate whether - in cholesteatoma epithelium - terminal differentiation,
resulting in high involucrin expression, is associated with mitogen-activated protein
kinase (MAPK) signaling.
Background:
Alterations in specific signal transduction pathways may explain abnormal
differentiation of the keratinocytes in cholesteatoma. Signaling pathways used by
eukaryotic cells to transduce extra cellular signals into cellular responses converge
on activated mitogen-activated protein kinases, mainly extracellular signal-regulated
kinase, c-Jun NH2-terminal kinase and p38.
Materials and Methods:
Tissue samples were taken from 16 patients with acquired cholesteatoma. Histologic
examination showed that 12 of the 16 cholesteatoma were inflamed.
Immunohistochemical methods were used to determine expressions of involucrin
and the activated form of p38 (pp38), extracellular signal-regulated kinase and c-
Jun NH2-terminal kinase proteins. The results obtained from cholesteatoma tissue
were compared with paired control samples from retro-auricular skin
Results:
We demonstrated increased levels of involucrin and increased levels of the activated
forms of p38 and ERK1/2 in cholesteatoma epithelium when compared with control
samples. No abnormality was found in the activation and expression of JNK1/2. A
positive correlation was found between pp38, pERK1/2, and involucrin expression
(p<0.05).
Conclusions:
Our results demonstrate that signaling via the mitogen-activated protein kinases
ERK1/2 and p38 is increased in cholesteatoma epithelium when compared with
control skin. The correlations between involucrin- and phosphorylated pERK1/2
expression and between involucrin - and phosphorylated p38 expression indicates
that terminal differentiation in cholesteatoma epithelium proceeds via activation of
these mitogen-activated protein kinase signaling pathways. We discussed whether
this increased mitogen-activated protein kinase-driven terminal differentiation is
probably part of a keratinocyte survival program or caused by an inflammation-
induced cellular stress response.
Introduction
In normal human epidermis, the process of terminal differentiation is tightly
controlled and takes place in its suprabasal layers. One of the main proteins involved
in this process is involucrin, the precursor of the keratinocyte cornified envelope,
which is selectively expressed in the upper suprabasal layers. The final product, a
thin layer of cornified envelopes, is continually shed from the surface of the
epidermis. This requires a regular supply of de novo differentiated cells. In
cholesteatoma, this process differs from the normal situation1. Terminal
differentiation of cholesteatoma epithelium is aberrant and is characterized by
involucrin expression in all suprabasal cell layers, which results in massive
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accumulation of keratin debris1. Cells respond to extracellular signals by transmitting
intracellular instructions to coordinate fundamental cellular responses. The mitogen-
activated protein kinase (MAPK) cascades are among the best characterized of
these intracellular signaling pathways. In mammalian cells, these MAPK cascades
consist of three distinct kinase routings downstream. These pathways include Ras/
Raf/ MEK1/ ERK1/2 (MAPK ERK kinase1/ extracellular-regulated kinase1/2), Ras/
JNK/ SAPK (c Jun N-terminal kinases/ stress-activated protein kinases) and the
Ras/ p38 MAPKs. Activated and, thus, phosphorylated MAPKs translocate to the
nucleus, where they activate transcription factors and target genes (Fig.1)2. Efimova
et al. has demonstrated that among the MAPKs, p38 is probably the most important
kinase, which is required for human involucrin promoter activation3. Parallel
pathways, however, might also play a role, such as the Ras/ ERK1/2-p384 and Ras/
ERK1/2-JNK5 pathways in psoriasis, indicating that different signaling pathways
may be active in keratinocytes. For a better understanding of the molecular basis
of cholesteatomal terminal differentiation, we studied which MAPK signaling
pathways are involved in this process. For this purpose, we determined the
expressions of activated ERK1/2, JNK, p38, and the corresponding expression of
involucrin. The results obtained from cholesteatoma tissue were compared with
paired control samples from retroauricular skin.
Figure 1. The classic MAPK cascade consists of three sequental intracellular activation steps
and is initiated when the first member, MAPKKK, is activated. MAPKKK activates MAPKK.
Subsequently, MAPKK activates a MAPK. There are three MAPK pathways downstream including
Ras/ Raf/ MEK1/ ERK, Ras/ MEKK1/ MEK4/ JNK/ SAPK and the Ras/ MEKK1/ MEK3/ p38 MAP




Clinical and histopathological data
Cholesteatoma specimens and biopsy specimens of retro-auricular skin were
obtained from 16 patients. The samples were placed in phosphate-buffered saline
immediately after the operation. The Committee of Medical Ethics of the Leiden
University Medical Centre approved the protocol. The specimens were prepared for
histological examination by fixation in 4% buffered formaldehyde for 20 hours
followed by dehydration in ethanol and embedding in paraffin wax.
Immunohistochemistry
Sections of 4 μm were taken from each tissue block. The first and the last sections
were stained with hematoxylin and eosin. The sections were immunostained with
antibodies, respectively, against phosphorylated-ERK1/2 (pERK1/2)(Thr202/
Tyr204), phosphorylated-JNK/SAPK (pJNK/SAPK)(Thr183/Tyr185), phosphorylated-
p38 (pp38)(Thr180/Tyr182) (clone 12F8) and involucrin (clone SY5). Anti-pERK1/
2, anti-pJNK/SAPK and anti-pp38 were obtained from Cell Signaling Technology
(Beverly, MA, U.S.A). Anti-involucrin was purchased from Sigma-Aldrich (Saint Louis,
Mo, U.S.A). The dilutions used were as follows: anti-pERK1/2, 1:200; anti-JNK/
SAPK, 1: 50; anti-pp38, 1:50; and anti-involucrin, 1: 10,000. Sections from the
same tissue served as negative controls (i.e. the primary antibody was omitted).
Sections from colon carcinoma (pERK1/2), mammacarcinoma (pp38 and pJNK/
SAPK) and abdominal skin (involucrin) were used as positive controls. The
expressions of pERK1/2, pJNK/SAPK, pp38 and involucrin were determined using
indirect immunoperoxidase methods. After deparaffination, all sections were treated
with tris buffered saline (TBS) containing 0.3% hydrogen peroxide for 10 minutes
to inactivate endogenous peroxidase. The sections assigned for pERK1/2, pJNK/
SAPK and pp38, were subjected to microwave antigen retrieval in boiling citrate
buffer (0.01mol/L, pH 6.0, for 10 minutes)6. These sections were, before
immunolabeling, pretreated with TBS/0.1% Tween for 5 minutes. The sections
were then incubated with the primary antibodies against pERK1/2, pJNK/SAPK,
and pp38, in TBS/0.1% Tween, overnight at  4°C. After washing in TBS, the sections
were incubated with ChemMate Envision (anti-rabbit; DAKO, Glostrup, Denmark)
for 30 minutes at room temperature (RT) and developed with 3,3'-diaminobenzidin
(DAB+) chromogen (1:50, for 5 minutes RT; DAKO). The sections for anti-involucrin
immunolabeling were incubated overnight at RT. They were then washed with TBS,
incubated with the appropriate biotinylated secondary antibody for 30 minutes at
RT, washed with TBS, and subsequently incubated with peroxidase-conjugated
streptavidin (DAKO) at RT for 30 minutes. They were then treated with DAB




 for 15 min. All sections were counterstained
with hematoxylin for 1 minute.
Morphometric analysis of immunohistochemical data
For each of the immunohistochemical markers studied, DAB-positive cells were
counted using an image analysis system (Leica Microsystems Imaging Solutions
Ltd. Cambridge, U.K.). The microscope was a Leica DMLB with N Plan 20 x 0.4
objective and a Leica DC 200 digital camera. The computer-assisted system used
to determine the immunohistochemical positive staining has been described
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elsewhere7. For each section, images from at least five different areas were stored
as digitized images. For cell counting, the same areas of the sections, but with
various antibodies, were used. The epithelial compartment was delineated on the
screen and the positive and negative cells were counted automatically. In each
section more than 1,000 cells were counted, and the percentage of positive cells
was calculated. For determining involucrin-positivity, in each section, on 25 different
locations of the epithelium the thicknesses of the involucrin-positive layer and the
total epithelium were measured. The percentage of the involucrin-positive layer
was then calculated with regard to the total thickness.
Data analysis and statistics
Data are expressed as means ± SD. Because of a non-Gaussian distribution of
parameters, we used the non-parametric Wilcoxon signed-rank test for comparison
of the differences between protein expressions in cholesteatoma and retro-auricular
skin. The level of significance was at p< 0.05. The Spearman’s rank correlation test
was used to calculate correlations. Correlation was considered significant at the
0.05 level. The SPSS Version 10 software package (SPSS, Inc.,Chicago, IL, U.S.A.)
was used for the calculations.
Results
Histopathological findings
In 12 of the 16 cholesteatoma samples, we found signs of inflammation:
inflammatory cells, newly formed blood vessels in the connective tissue and locally
thickened epithelium. In two tissue samples, there was insufficient connective tissue
for analysis. In the retroauricular skin sections, there was no evidence of
inflammation.
Expression of pErk1/2, pJNK/SAPK, pp38 and Involucrin
The expression of pERK1/2 in cholesteatoma epithelium was mainly nuclear and
localized in all layers of the cholesteatoma epithelium (Fig. 2A). This observation
was consistent with the expression of pERK1/2 in retroauricular skin. On average,
the cholesteatoma samples had a significantly increased percentage of pERK1/2-
positive cells, when compared with retroauricular skin (p=0.001). Cholesteatoma
epithelium was more positive than control epithelium in 94% of the pairs examined.
The average percentages of pErk1/2-positive cells in retroauricular skin and
cholesteatoma epithelium are summarized in Table 1. In cholesteatoma epithelium
nuclear expression of pJNK/SAPK was present in all epithelial layers (Fig. 2B). This
was consistent with the expression pattern in retroauricular skin. We found 44% of
the cholesteatoma epithelium more positive than control epithelium, which was
not a significant difference. The average percentages of pJNK-positive cells in
retroauricular skin and cholesteatoma epithelium are summarized in Table 1. In
cholesteatoma, the nuclear expression of pp38 was positive in all suprabasal layers.
In some cholesteatoma, pp38 expression was also present in the basal epithelial
layers (Fig. 2C).Cholesteatoma epithelium was more positive than control epithelium
in 75% of the pairs examined. When compared to retroauricular skin, the average
percentage of pp38 was significantly increased in cholesteatoma tissue (p=0.003).
The average percentages of pp38-positive cells in retroauricular skin and
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cholesteatoma epithelium are summarized in Table 1. Involucrin expression was
prominently present in all suprabasal layers in cholesteatoma epithelium and
sometimes also in the basal layers (Fig 2D). This was in contrast with retroauricular
skin in which the involucrin expression was mainly present in the upper suprabasal
layers. In 100% of the cases, cholesteatoma epithelium was more positive than
control epithelium of the pairs examined. Compared with retro-auricular skin, the
percentage of involucrin positivity in cholesteatoma epithelium was significantly
increased (p<0.001). The average involucrin positivity is presented in Table 1.
Associations of pErk1/2, pJNK/SAPK, pp38 and involucrin with
inflammation
The epithelial expressions of pERK1/2, pJNK/SAPK, pp38, and involucrin of all
cholesteatoma samples showed large intra- and interindividual variations. Protein
expressions were within the limits of this variance when comparing inflamed
cholesteatoma samples with those in which we found no signs of inflammation.
For this reason, no correlation between protein expression and inflammation could
be established.
Associations of pErk1/2, pJNK/SAPK, pp38 and involucrin
Using the Spearman’s rank correlation test, a significant positive association was
observed between involucrin and pERK1/2 expression (p= 0.02) and between the
expression of involucrin and pp38 (p=0.02). Even after control of basal protein
expression level per patient, these correlations persist. We did not find any
correlation between the other proteins.
Discussion
In the current study, we report that phosphorylated ERK1/2 and phosphorylated
p38 are prominently present in cholesteatoma epithelium. We found that the
presence of pERK1/2 and pp38 was positively associated with the expression of
involucrin. Activated JNK expression did not differ from that in normal skin. In
cholesteatoma epithelium MAPK signaling with relation to involucrin expression
Table 1. Percentages of pERK1/2-, pJNK/SAPK- and pp38-positive cells in control skin and
cholesteatoma epithelium.
 aInvolucrin positivity is expressed as the percentage of epithelium stained when compared
to the total thickness.
65
Terminal differentiation and MAPK signaling
5
Figure 2. Immunohistochemical localization of pERK1/2, pJNK/SAPK, pp38, and involucrin in
paraffin sections of human cholesteatoma epithelium and paired retro-auricular skin; (A and
B) pERK1/2-positive cells are expressed in all epithelial layers; (C and D) pJNK/SAPK-positive
cells are expressed in all layers of the epithelium; (D and E) pp38-positive cells are mainly
expressed in all suprabasal layers, but sometimes in cholesteatoma epithelium also in the
basal layers;(F and G) involucrin in cholesteatoma epithelium, positive cells are mainly
expressed in suprabasal layers but also in basal layers, and in retroauricular skin involucrin-
posititive cells are mainly expressed in the upper suprabasal layers. Original magnification:
x200. Ep, epithelium; CT, Connective Tissue
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has, to our knowledge, never been reported before.
It has been demonstrated in vitro that different agents such as calcium, vitamin A,
protein kinase C activators, cytokines and antioxidants, can regulate involucrin
gene expression3,8. Efimova et al. reviewed the basic role of MAPK cascades in
these involucrin promoter-activating mechanisms3,9. These articles contribute to
the understanding regarding the mechanisms that regulate keratinocyte
differentiation. In keratinocytes however, when different cytokines and growth factors
are present, MAPK signaling may even cause opposing effects on involucrin
transcription10. In cholesteatoma numerous different cytokines and growth factors
have been demonstrated1. In our experiments, we found as a net result an increased
involucrin expression, which has been demonstrated previously11. We also found
involucrin expression associated with both an increased pERK1/2 and an increased
p38 activation. This result is in contrast with previous articles in which p38 signaling
was mentioned to be the most important involucrin regulatory mechanism in
keratinocytes 3. We also could not confirm the finding of Efimova et al. concerning
the p38-related synchronous reduction in ERK1/2 activity9. There may be different
explanations for this. Differences between keratinocytes in vitro versus in vivo
analysis, as well as differential cytokine and growth factor triggering, may account
for variations in MAPK signaling12. In agreement with these arguments and with
our report is that, in psoriatic skin lesions, a similar MAPK activation pattern, normal
pJNK expression, and increased pERK1/2 and pp38 expression, have been
demonstrated4. Interestingly, it has been reported that, in psoriasis, involucrin
expression is increased13.
Various conditions may therefore lead to parallel pERK1/2 and p38 pathway
activation. In cholesteatoma, growth factors and cytokines may activate different
receptors. Growth factor receptor activation initiates the MAPK/ERK1/2 signaling
pathway, whereas proinflammatory cytokines such as IL-1 and tumor necrosis factor-
α regulate p38 signaling4. In cholesteatoma epithelium, the general cellular stress
response may then be a parallel ERK1/2 and p38 signaling and subsequent
augmented involucrin upregulation.
However, there may be another reason for differential ERK1/2 and p38 activation:
keratinocytes that lose their contact with the epidermal basal membrane rapidly
differentiate and keratinize14. The increased differentiation and subsequent
keratinization in cholesteatoma epithelium shows remarkable similarity with this
process. In general, however, when epidermal cells lose their contact with the
extracellular matrix they rapidly become apoptotic, a process called anoikis14.
Protection of epithelial cells against anoikis is associated with and requires sustained
ERK1/2 MAPK phosphorylation15. It has also been demonstrated that inhibition of
ERK signaling leads to apoptosis of keratinocytes16. This survival mechanism is of
importance in tissue repair processing for migrating keratinocytes at the leading
edge of a cutaneous wound.
This anchorage-independent survival of keratinocytes might also arise in
cholesteatoma in which an aberrant and disrupted basal membrane has been
demonstrated17.  In addition, cholesteatoma keratinocytes are known to be
migrative18. Anchorage-independent survival of cholesteatoma keratinocytes is also
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in line with our previous findings demonstrating sustained active ERK1/2 expression
and minimal apoptosis19,20.
We therefore postulate that, in cholesteatoma epithelium, terminal differentiation
is mediated by both, pERK1/2 and p38 MAPK activation. Whether this is part of an
inflammation- induced cellular stress response and/ or part of a keratinocyte survival
program during wound healing needs to be investigated. Future research will be
focused on the role of different cytokines involved in cholesteatoma
hyperdifferentiation.
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Background: In a previous report, we have demonstrated minimal apoptosis in
cholesteatoma epithelium. The phosphoinositide 3-Kinase/ Akt/Protein Kinase B
(PI3K/ Akt/PKB) and the mitogen activated protein kinases (MAPK) signaling
transduction pathways have been reported to protect epithelial cells against
apoptosis. Both pathways have also been proven to regulate late terminal
differentiation of keratinocytes. In cholesteatoma epithelium, we recently have
shown MAPK activation, associated with terminal differentiation.
Objective: To investigate whether in human cholesteatoma epithelium protection
against programmed cell death by means of PI3K/ Akt survival signaling is present
and associated to MAPK activation and terminal differentiation.
Design: 15 samples of cholesteatoma and 15 paired control retro-auricular skin
samples were immunohistochemically stained for pAkt/PKB, phosphorylated
extracellular regulated kinase1/2 (pERK1/2) phosphorylated JNK/SAPK,
phosphorylated p38, involucrin and filaggrin. Positive cells were counted by
computer-assisted digital image analysis.
Subjects: Human acquired cholesteatoma and patient-matched retro-auricular
skin were collected during surgical eradication of the cholesteatomas.
Results: The protein expressions of pAkt/PKB, pERK1/2, pp38, and involucrin in
cholesteatoma epithelium were significantly increased when compared to retro-
auricular skin (p <0.01). Filaggrin expression was significantly decreased (p=0.03).
The positive correlation was confirmed between both, pERK1/2 and pp38, and
involucrin (p<0.05).
Conclusions: There is a strong indication that epithelial keratinocytes in
cholesteatoma are protected against apoptosis. The late terminal differentiation
program in cholesteatoma epithelium is disturbed.
Introduction
Cholesteatoma is a gradually expanding destructive epithelial lesion of the temporal
bone. Insight into its exact pathogenesis remains incomplete. There is increasing
evidence that acquired cholesteatoma behaves as a chronic wound-healing process
with often an inflammatory tissue repair reaction1. The injury is regarded as a
weakening and/ or perforation of the tympanic membrane and a subsequent invasion
of external ear keratinocytes into the middle ear cleft2. Chronic middle ear
inflammation is usually the preceding event. In general, inflammatory (oxidative)
stress is a common phenomenon in cholesteatoma. Inflammatory signals induce a
variability of cellular responses in which programmed cell death is a regular outcome3
In cholesteatoma epithelium, an increased apoptosis has been reported4,5. However,
by TUNEL assay and active Caspase 3 immunohistochemistry, we could not confirm
these results6. We therefore hypothesize, that in cholesteatoma epithelium
keratinocytes are protected against programmed cell death. The most prominent
candidate process for survival of epithelial cells is the phosphoinositide 3- Kinase/
Akt/protein kinase B (PI3K/ Akt/PKB) signaling pathway7,8. PI3K/ Akt/PKB is activated
in cells  exposed to diverse stimuli such as hormones, growth factors and integrin
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ligation to extracellular matrix components. Activation of Akt/PKB by phosphorylation
at position Ser 473 has been demonstrated to lead to increased keratinocyte
survival7. The PI3K/ Akt/PKB signaling pathway however, is not the only survival
pathway in epithelial cells. The extracellular regulated kinase1/2 (ERK1/2), a
member of the mitogen activate protein kinases (MAPK), has also been reported to
protect epithelial cells from apoptosis9,10. MAPKs are a family of proteins, which are
the targets for diverse extracellular stimuli that mediate a series of distinct signaling
cascades. MAPK signaling is important in the regulation of a multitude of cellular
functions, such as proliferation, differentiation, and apoptosis, as well as
development, growth, and inflammation11. Although PI3K/ Akt/PKB and MAPK
pathways are seemingly independent, they appear to be both essential for epithelial
survival. Interestingly, different reports mention that there is correspondence
between the pathways leading to keratinocyte survival and terminal
differentiation12,13. Calautti et al revealed that PI3K signaling to Akt promotes
keratinocytes differentiation versus death. They demonstrated that inhibition of
PI3K caused a significant decrease in the amount of the late terminal differentiation
markers, loricrin and filaggrin14. Efimova et al reviewed the basic role of MAPK
signaling in which MAPK member p38, in concert with pERK1/2, promotes the
transcription of involucrin, an early terminal differentiation marker15. In
cholesteatoma epithelium, besides minimal apoptosis, we have shown ERK1/2 and
p38 MAPK activation, to be associated with terminal differentiation6. However, to
our knowledge, the expression of the communicating survival and differentiation
pathway PI3K/Akt has not been investigated. We therefore questioned whether in
cholesteatoma epithelium protection against programmed cell death by means of
PI3K/ Akt signaling is present and if present, whether this survival signaling is
associated to MAPK-activation and terminal differentiation. To investigate this, we
determined the expression of the activated downstream effectors of the PI3K/ Akt
and MAPK pathways resp phospho-Akt (pAkt), phospho-ERK1/2 (pERK1/2),
phospho-SAPK/JNK (pSAPK/JNK) and phospho-p38 (pp38) as well as involucrin
and filaggrin as terminal differentiation markers by quantitative
immunohistochemistry and we correlated their expression level.
Materials and methods
Clinical and histopathological data
Acquired cholesteatoma specimens and biopsies of retro-auricular skin were obtained
from fifteen patients. The samples were placed in phosphate-buffered saline
immediately after the operation. The Committee of Medical Ethics (CME) of the
Leiden University Medical Centre approved the protocol. The specimens were
prepared for histological examination by fixation in 4% buffered formaldehyde for
20 hours followed by dehydration in ethanol and embedding in paraffin wax
Immunohistochemistry
Sections of 4 ìm were taken from each tissue block. The first and the last sections
were stained with hematoxylin eosin. The antibodies used were against phospho-
Akt (Ser473;1:150), phospho-ERK1/2 (Thr202/Tyr204;1:200), phospho-SAPK/JNK
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(Thr183/tyr185;1:50), phospho-p38 (Thr180/Tyr182, clone 12F8;1:50) all from
Cell Signaling Technology (Beverly, MA, USA). Anti-involucrin (clone SY5; 1:10,000)
and anti-filaggrin (15C10; 1:3000) were purchased from respectively Sigma-Aldrich
(Saint Louis, Miss, USA) and Monosan (Uden The Netherlands). Kidney sections
with diabetic nephropathy (pAkt), colon carcinoma (pERK1/2), mamma carcinoma
(pp38 and pSAPK/JNK) and abdominal skin (involucrin and filaggrin) were used as
positive controls. Sections from the same tissue served as negative controls, i.e.
the primary antibody was omitted.
To inactivate endogenous peroxidase, the deparaffinized sections were treated with
Tris-Buffered Saline (TBS) containing 0.3% hydrogen peroxide for 20 minutes. The
sections were then subjected to microwave antigen retrieval in citrate buffer (0.01M,
pH 6.0, 12 min.)16. To determine protein expressions an indirect immunoperoxidase
method was used. Briefly, after antigen retrieval all sections were incubated with
the primary antibody overnight at 4°C. After washing in TBS the sections were
incubated with ChemMate Envision (anti-rabbit and anti-mouse DAKO, Glostrup,
Denmark) for 30 min. at RT and developed with 3,3'-diaminobenzidin chromogen
(DAB+, 1:50, 5 min. RT, DAKO, Glostrup, Denmark). The sections were
counterstained with hematoxylin for 1 min.
Morphometric analysis of immunohistochemical data
The sections were analyzed using an image analysis system (Leica Microsystems
Imaging Solutions Ltd. Cambridge, UK.). The microscope was a Leica DMLB with N
Plan 20x0.4 objective and a Leica DC 200 digital camera. The computer-assisted
system used to determine the immunohistochemical positive staining has been
described elsewhere17. For each section, images from at least five different areas
were stored as digitized images. For cell counting the same areas of the sections,
but with various antibodies, were used. The epithelial compartment was delineated
on the screen and the positive and negative cells were counted automatically. In
each section > 1000 cells were counted, and the percentage of positive cells was
determined. For determining involucrin- and filaggrin positivity, in 25 different
locations of the epithelium the thicknesses of the DAB positive layers and the total
epithelium were measured. The percentages were then calculated with regard to
the total thickness.
Data analysis
Data are expressed as means ± SD. In order to compare the means of paired
variables, we used the paired samples t-test. The level of significance was at p<
0.05. The Pearson’s correlation test was used to calculate correlations. Correlation
was considered significant at the 0.05 level. The SPSS10 software package (SPSS,
Chicago, IL, USA) was used for the calculations.
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In twelve out of the fifteen cholesteatoma samples we found signs of inflammation:
a locally thickened and hyperproliferative epithelium and in the connective tissue
inflammatory cells and newly formed blood vessels. In two tissue samples there
was insufficient connective tissue for analysis. We found no evidence of inflammation
in the retro-auricular skin sections.
Immunohistochemistry
Cytoplasmic expression of pAkt in cholesteatoma epithelium was focally
localized, from the lower suprabasal layers till the stratum granulosum and stratum
corneum. In the retro-auricular skin, cytoplasmic pAkt was found only in some
cells in the basal layers. Nuclear expression of pAkt was sometimes present in
cholesteatoma as well as retro-auricular skin epithelium (Fig.1G and J). Of the
pairs examined, 93 % of the cholesteatoma epithelium was more positive than its
control sample. The average pAkt expression in cholesteatoma epithelium was
significantly increased when compared to retro-auricular skin (p<0.001). The
average percentages are listed in Table 1.
In cholesteatoma and control tissue, pERK1/2 expression was mainly nuclear
and localized in all layers of the epithelium (Fig.1A and D). We found all
cholesteatoma epithelia more positive than its control. On average, the
cholesteatoma samples had a significantly increased percentage of pERK1/2-positive
cells, when compared to retro-auricular skin (p<0.001). The average percentages
are summarized in Table 1.
In cholesteatoma epithelium nuclear expression of pJNK/SAPK was present
in all epithelial layers (Fig.1B). This was consistent with the expression pattern in
retro- auricular skin (Fig.1E). We found 40% of the cholesteatoma epithelium more
positive than control epithelium, which was not a significant difference. The average
percentages of pJNK-positive cells in retro-auricular skin and cholesteatoma
epithelium are summarized in Table 1.
The nuclear expression of pp38 was positive in all cholesteatoma suprabasal
layers and sometimes also in the basal layers (Fig. 1C ). This expression pattern
was also observed in control skin (Fig.1F) In 80% of the pairs examined,
cholesteatoma epithelium was more positive than control epithelium. When
compared to retro-auricular skin, the average percentage of pp38 in cholesteatoma
tissue was significantly increased (p<0.001). The average percentages of pp38-
positive cells in retro-auricular skin and cholesteatoma epithelium are expressed
in Table 1.
Involucrin expression was prominently present in all suprabasal layers in
cholesteatoma epithelium and sometimes also in the basal layers (Fig. 1H). This
was different from retro-auricular skin in which the involucrin expression was mainly
present in the upper suprabasal layers (Fig. 1K). We found in all of the pairs examined
cholesteatoma epithelium more positive than its control. When compared to retro-
auricular skin, the percentage of involucrin positivity in cholesteatoma epithelium
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was significantly increased (p<0.001). The average involucrin positivity is presented
in Table 1.
In cholesteatoma epithelium, filaggrin expression was in general diverse,
it was often absent or modestly present, but it was also focally increased and
extended from the stratum granulosum to the stratum corneum (Fig.1I). This was
in contrast with the control skin, in which filaggrin was equally expressed in the
stratum corneum (Fig. 1L). In 73% of the pairs examined filaggrin expression was
decreased in cholesteatoma epithelium when compared to its control skin, which
was a significant difference (p=0.003). The average percentages are summarized
in Table 1.
Associations of pAkt, pERK1/2, pJNK/SAPK, pp38, involucrin and filaggrin
Using the Pearson’s correlation test, a significant positive association was observed
between involucrin- and pERK1/2 expression (p= 0.05) and between the expressions
of involucrin and pp38 (p=0.04).
Discussion
In this study we demonstrated that in cholesteatoma epithelium active Akt is present.
When compared to control skin the expression of activated Akt was significantly
increased. Filaggrin expression on the contrary, when compared to control skin,
was virtually absent, although some focal strong positivity was observed in individual
cases. As previously demonstrated, ERK1/2 and p38 MAPK activation was increased
and associated with involucrin expression.
Phosphorylated Akt has been extensively reviewed as a promoter of cell survival7,18.
It operates via multiple mechanisms such as maintaining mitochondrial integrity
and the phosphorylation and thus inactivation of the pro-aptotic protein BAD7,18.
The increased presence of activated Akt in cholesteatoma epithelium may therefore
indicate protection against programmed cell death, which is in line with our previous
findings. PI3K/ Akt signaling also has been demonstrated to be involved in late
Table 1.
Percentages of pERK1/2, pJNK/SAPK, pp38, pAkt, involucrin and filaggrin-positive cells in
control skin and cholesteatoma epithelium. Involucrin and filaggrin positivity is expressed as
the percentage of epithelium stained when compared to the total thickness.
* p<0.001; ** p0.003 versus control skin
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terminal differentiation, however, we were not able to establish an association
between pAkt and filaggrin14. Instead, the overall filaggrin expression was decreased
when compared to control skin. This is in contrast with a previous report in which
filaggrin expression in cholesteatoma epithelium has been found to be increased19.
Different types, differential heterogeneity of cholesteatoma tissue or the stage of
development may account for this discrepancy. Alternatively, in different keratotic
skin diseases such as psoriasis and granular parakeratosis an absence or reduction
in the amount of filaggrin has been reported 20-22. In one of these reports it has
been mentioned that augmented apoptosis explains the diminished presence of
late terminal differentiation markers in psoriasis21. In that study the TUNEL assay
has been used but in another study DNA analysis revealed that psoriatic
keratinocytes have intact DNA23. Metze et al suggested that abnormalities of cell
surface adhesion structures might account for the dysregulation of the cornified
envelope components22. This has recently been supported in the report of Calautti,
in which evidence has been provided that differentiation-specific activation of the
PI3K pathway requires the cadherin-catenin adhesion complexes14. Thus, protection
against apoptosis occurs by activated Akt, but initiation of late terminal differentiation
needs an additional component: cell adhesion. In their analysis of cholesteatoma
tissue integrity Naim et al found, contrary to normal skin, that beta-catenin was
diminished or absent in cholesteatoma suprabasal layers24. Their proposal that
matrix metalloproteases (MMPs) play a prominent role in this process may hold
true, because MMP activity has been frequently reported in cholesteatoma25.
MAPK activation has been reported to generate early terminal differentiation by
promoting involucrin transcription15. Interestingly, sustained ERK1/2 MAPK activation
is required for anchorage-independent survival of epithelial cells10.
The increased presence of the activated ERK1/2, p38 MAPK and involucrin and
their associations in cholesteatoma epithelium indicate, that the MAPK early terminal
differentiation pathway is active. Increased presence of activated Akt, however, is
in the greater part of cholesteatoma epithelium not followed by filaggrin expression.
It appears therefore that the process of late terminal differentiation is abrogated
and that keratinocytes are arrested in an early terminal differentiation stage. This
phenomenon has also been described for other keratotic skin diseases22. The defect
in the production of filaggrin may result in a failure to degrade keratohyalin
granules22. This may explain the conspicuous granular appearance of the
cholesteatoma cornified layer 1. In summary, we established increased activated
Akt in cholesteatoma epithelium, which was not associated to MAPK-mediated
terminal differentiation. In the reduction of filaggrin expression in cholesteatoma
epithelium we found a disturbed late terminal differentiation program consistent
with other keratotic skin diseases. Our future research will concern cytokine/ growth
factor involvement in cholesteatoma terminal differentiation.
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Immunohistochemical analysis/ staining of paraffin sections of human cholesteatoma
epithelium (A,B,C,G,H,I) and retro-auricular skin(D,E,F,J,K,L). Localization of p ERK1/2(A,D),
pJNK/SAPK(B,E), pp38(C,F), pAkt(G,J), involucrin(H,K) and filaggrin(I,L) in Original
magnification: x 200.
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Cholesteatoma is a non-malignant, destructive lesion of the temporal bone that
gradually expands and causes complications by erosion of the adjacent bony
structures. The consequences can be as severe as facial paralysis and intracranial
complications. Until now, surgery is the only treatment of choice. The pathogenesis
of cholesteatoma remains still controversial. Current concepts postulate that
cholesteatoma may be considered a wound healing process, although formal proof
is lacking as yet. Several reports provide evidence for the involvement of TGFβ in
both normal and abnormal wound healing. In the present study, quantitative
immunohistochemical analysis was performed to examine the expression of TGFβ,
the activated form of its intracellular effector, phosphorylated-Smad2 (pSmad2),
its natural inhibitor Smad7 and target gene EDA-positive fibronectin (EDA-FN). In
12 cholesteatoma and control samples protein expressions showed consistent
relationships among TGFβ, nuclear pSmad2 and Smad7. We found concordant
expressions of TGFβ and nuclear p-Smad2 in cholesteatoma epithelium and its
control. Epithelial Smad7 expression was significantly reduced in cholesteatoma
when compared to control epithelium (p=0.04). In cholesteatoma extracellular
matrix (ECM), a significantly increased TGFβ and nuclear pSmad2 was demonstrated
(p<0.01). Smad7 expression in the ECM was comparable in cholesteatoma and
its control. EDA-FN deposition in cholesteatoma ECM was excessive whilst EDA-FN
expression was absent in controls. Our results confirm reports of in vitro
experiments and support the concept that cholesteatoma behaves like a chronic
wound healing process.
Keywords: pSmad2, Smad7, Fibronectin EDA, wound healing.
Introduction
Cholesteatoma has been described since the 17th century and has been the subject
of extensive research. Two main types of cholesteatoma have been described:
congenital, which occurs behind an intact tympanic membrane, and acquired.
Acquired cholesteatoma can appear as a limited diverticulum of the pars flaccida
but also with posterosuperior eardrum perforations1. This type is usually associated
with inflammatory reactions in the middle ear cavity and in active cholesteatoma
inflammatory granulation tissue often appears along the invading epithelium1.
Although the origin of cholesteatoma is not clear, the migration theory, in which
keratinocytes from the external ear canal migrated into the middle ear cavity,
forming a pathological collision with middle ear mucosa is generally accepted. As
a result of this collision, cholesteatoma epithelium and stroma are entangled (Fig.
1), which makes separate analysis virtually impossible.
There is still a difference of opinion concerning cholesteatoma pathogenesis, and
different hypotheses have been proposed.  Among current concepts it is postulated
that cholesteatoma can be considered as disturbed wound healing2. Pressure-
induced invaginations, morphological changes of the tympanic membrane (TM) or
even perforation of the TM result in enough damage to induce wound-healing
processes2. Wound healing is a complex process, which involves a series of
overlapping stages subdivided in inflammation, granulation formation, extracellular
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Figure 1. Hematoxylin-eosin staining of cholesteatoma. Clearly visible is the entanglement
between epithelium and connective tissue.
matrix production as well as tissue remodeling3. When this delicate balance is
disturbed in skin tissue, chronic fibrosis and keloid-formation can be the result.
Many reports provided evidence that TGFβ is one of the key factors involved in
wound healing3,4. TGFβ is able to affect proliferation and migration of different cell
types5,6. Moreover, TGFβ controls both the initiation and resolution of inflammatory
responses by chemotaxis, activation, survival and apoptosis of different
inflammatory cells such as lymphocytes, natural killer cells and macrophages7.
TGFβ is also able to bind to its own gene promoter resulting in amplified
biosynthesis4. Proper regulation of TGFβ signaling is therefore essential in normal
tissue repair. TGFβ  signal transduction is activated following ligand binding to the
type II TGFβ  receptor and, after heteromerization and transphosphorylation of
the type I TGFβ  receptor, signal propagation occurs by phosphorylation of the
receptor-specific (R) Smads (Smad2 and Smad3). The phosphorylated R-Smads
then oligomerise with Smad4, translocate to the nucleus and regulate the
transcription of target genes8. The TGFβ downstream signaling can be inhibited by
an antagonist of the Smad-family, Smad78. Association of different Smads and
Smad complexes with transcription factors and transcriptional co-activators/co-
repressors in the nucleus further regulates transcriptional control by TGFβ8. It is
recognised that after TGFβ-ligand binding to the receptor different other cellular
pathways can be stimulated9. Moreover, the pathways that are stimulated are
thought to be cell type specific9. In keratinocytes, TGFβ induces cell cycle arrest
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through the induction of p21cip1/waf1 transcription10.  In fibroblasts, however, TGFβ
signaling induces proliferation, and as a result of this, collagen production4. In
cholesteatoma tissue, because of the presence of many different types of cells in
the epithelium and stroma, bioactivation of TGFβ is rather complex. To investigate
TGFβ bio activation in cholesteatoma, we established TGFβ-induced downstream
signaling in both, cholesteatoma epithelium and extracellular matrix. We therefore
examined the expression patterns of TGFβ, its activated downstream effector
phosphorylated-Smad2 (pSmad2) and the TGFβ signaling antagonist Smad7. Bio
activating of TGFβ has been shown to result in alternative splicing of fibronectin
transcripts11. The EDA+ FN, isoform is usually seen in fetal and tumor cells and
during wound healing but not in normal adult cells12,13. Inclusion of the EDA region
has also been reported to be essential for normal wound healing14, although
accumulation of EDA-positive fibronectin protein can also be present in fibrotic
lesions15. For these reasons we focussed our analysis on the expression of this
extracellular matrix isoform as a marker for TGFβ bioactivation.
Materials and Methods
Clinical and histopathological data
Cholesteatoma specimens and biopsies of retro-auricular skin were obtained from
twelve patients. The Committee of Medical Ethics of the Leiden University Medical
Center had approved the protocol. The specimens were prepared for histological
examination by fixation in 4% buffered formaldehyde for 20 hours, dehydration in
ethanol and embedding in paraffin wax.
Immunohistochemistry
The various protein expressions were visualized with an indirect immunoperoxidase
technique. We applied the following antibodies: TGFβ1(V), -pSmad2, -Smad7 and
-fibronectin EDA (IST-9). The dilutions used were 1: 50, 1:200, 1: 600 and 1:100
resp. The secondary antibody was ChemMate Envision (anti-rabbit, anti-mouse
DAKO, Glostrup, Denmark). Anti-TGF-β1 and fibronectin EDA were purchased from
respectively Santa Cruz Biotechnology, Inc.CA USA and Abcam Cambridge, UK.
The protein A affinity-purified pSmad2 and Smad7 rabbit polyclonal antibodies
have been published before16,17. Kidney sections with diabetic nephropathy were
used as positive controls. Sections from the same tissue served as negative controls,
i.e., the primary antibody was omitted. To inactivate endogenous peroxidase, the
deparaffinized sections were treated with methanol containing 3%
hydrogenperoxide for 20 minutes. After rehydration, the sections were subjected
to microwave antigen retrieval in citrate buffer (0.01M, pH 6.0, 12 min.)18. All
sections were incubated with the primary antibody overnight at 4ºC. and washed
in Tris-buffered saline (TBS). The specimens were incubated with the secondary
antibody for 30 min. at room temperature (RT), washed and subsequently incubated
with peroxidase-conjugated streptavidin at RT for 30 min. They were then treated
with 3,3´, di- aminobenzidine chromogen (DAB+, 1:50, 5 minutes at RT; DAKO,
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Glostrup, Denmark) and counterstained with hematoxylin for 1 min.
Morphometric analysis of immunohistochemical data
For each of the immunohistochemical markers studied, the DAB positive staining
was quantified using an image analysis system (Leica Microsystems Imaging
Solutions Ltd. Cambridge, UK.). The microscope was a Leica DMLB with a Leica DC
200 digital camera. The computer-assisted system used to determine the
immunohistochemical positive staining is described elsewhere19. From each section,
images of at least five different epithelial and adjacent subepithelial areas were
stored as digitized images. Cholesteatoma and retro-auricular skin samples were
included when sufficient stroma, i.e., ~25,000 μm2, was present. For cell counting
purposes, the same areas of the sections, but with various stains, were used. The
epithelial compartment was delineated on the screen and the positive and negative
cells were counted automatically. In each section more than one thousand cells
were counted, and the percentage of positive cells was determined.
Data analysis
Data values were expressed as means ± SD. Because of the non-parametric
distribution of the data, the non-parametric Wilcoxon test was used to compare
means of the paired variables, with p <0.05 was considered to be significant. To
calculate possible correlations, the Spearman’s test for non-parametric correlations
was used. Correlation was considered significant at the 0.05 level. The Statistical




At macroscopic and microscopic inspection all cholesteatoma were considered to
be inflamed. Microscopic inspection revealed in all cholesteatoma samples
inflammatory cells and newly formed blood vessels in the connective tissue. In the
retro-auricular skin sections there was no evidence of inflammation.
Epithelial expression of TGFβ, pSmad2 and Smad7.
In cholesteatoma epithelium and control skin, a predominant nuclear staining for
TGFβ and pSmad2 and a mainly cytoplasmic Smad7 staining was observed (Fig.2A-
F). In retro-auricular skin we sometimes also found nuclear Smad7 staining. TGFβ-
, pSmad2- and Smad7- positive cells were found in all layers of cholesteatoma
and control skin (Fig.2B, D, F). In cholesteatoma, Smad7 expression appears to
be less prominent in the basal layers when compared to the control (Fig. 2E,F).
The percentages of TGFβ and pSmad2-positive cells in cholesteatoma were similar
to those of retro-auricular skin (Fig.3). The percentage of Smad7 positive cells in
cholesteatoma epithelium was significantly lower when compared to retro-auricular
skin (Fig.3). In cholesteatoma, a positive correlation was established between
TGFβ and Smad7 and between pSmad2 and Smad7 (Table1). In retro-auricular
skin, we found no correlations.
Stromal expression of TGF ß, pSmad2, Smad7 and fibronectin EDA.
In cholesteatoma stroma, the percentages of TGFβ and pSmad2 were significantly
higher when compared to retro-auricular skin (Fig.4). There was no difference in
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Figure 2. Immunohistochemical localization of TGFβ, pSmad2, Smad7 and fibronectin EDA in
paraffin sections of control retro-auricular skin (A, C, E, G) and human cholesteatoma (B, D,
F, H). TGFβ-positive cells are prominently expressed in both, epithelium and stroma (A,B).
pSmad2-positive cells scatter through the epithelial cell layers and the stroma (C,D). Smad7
is expressed in various epithelial and stromal cells (E,F). Fibronectin EDA-positivity is only
present in cholesteatoma stroma (G,H). Original magnification: x 200  E= epithelium; CT=
Connective Tissue
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Figure 3. Represents average percentages of TGFβ, pSmad2 and Smad7 in cholesteatoma
epithelium and control skin.
Table 2, representing correlations (p-values) of TGFβ, pSmad2 and Smad7 in cholesteatoma
stroma. Numbers in bold represent significant correlations
stromal expression of Smad7 in cholesteatoma and that in the stroma of retro-
auricular skin. Fibronectin EDA in cholesteatoma stroma was abundantly expressed,
while in retro- auricular skin fibronectin EDA expression was absent (Fig 2G,H). In
cholesteatoma stroma, TGFβ, Smad2 and Smad7 showed significant positive
correlations (Table2). There were no correlations in stroma of retro-auricular skin.
Table 1, representing correlations (p-values) of TGFβ, pSmad2 and Smad7 in cholesteatoma
epithelium. Numbers in bold represent significant correlations.
Figure 4. Represents average percentages of TGFβ, pSmad2, Smad7 and fibronectin EDA in
cholesteatoma stroma and the stroma of control skin.
*= p<0.05; **= p<0.001.





Our data indicate that TGFβ bio-activation appears to be not upregulated in
cholesteatoma epithelium. Nevertheless, the correlations among TGFβ, pSmad2,
and Smad7 demonstrate that TGFβ signaling pathways are operational. However,
in spite of the decreased Smad7 expression these processes do not lead to a
significant nuclear pSmad2 expression. A decreased Smad7 expression has
previously been demonstrated in scleroderma skin, but in this tissue this was
followed by an enhancement in phosphorylation of Smad220. In scleroderma, Smad7
expression appears to be virtually absent while in cholesteatoma epithelium,
although decreased when compared to control skin, the average Smad7 positivity
was 20%. The competitive binding of Smad7 and Smad2/3 to the receptor site
may be regulated stoichiometrically, which may account for the fact that, in
cholesteatoma epithelium, Smad7 does not significantly inhibit Smad2 activation17.
Apart from inhibiting Smad2 activation, Smad7 has been reported to play
a critical role in mediating apoptosis by activation of the JNK signaling pathway21.
However, we previously demonstrated that in cholesteatoma epithelium JNK
signaling was not activated22. The decreased expression of Smad7 in cholesteatoma
epithelium is in line with these findings and may be part of a protective signaling
against apoptosis.
In this previous study we also demonstrated augmented ERK1/2/p38 MAPK
signaling in cholesteatoma epithelium22. Moreover, it has been reported that in
keratinocytes, TGFβ and MAPK signaling requires cooperative signaling to become
more effective23-25. In a pilot experiment, we found significant correlations between
TGFβ, pSmad2 and pERK1/2 in cholesteatoma (n=7; p=0.02 and p=0.03,
unpublished results), but no correlations in control skin. These preliminary results
indicate that, in cholesteatoma epithelium, TGFβ and pSmad2 may be involved in
MAPK signaling. We hypothesize that, in cholesteatoma epithelium default levels
of TGFβ may become effective because of cooperative signaling, leading to
augmented transcription of several genes. One of these genes may be p21cip1/waf1,
which we previously found to be increased and associated with pERK1/2
expression26.
This phenomenon as observed in cholesteatoma may also be of importance
in the molecular understanding of transient versus irreversible epithelial
mesenchymal transition (EMT). Cholesteatoma keratinocytes share many features
with EMT, such as migration, spindle-like morphology, augmented ERK1/2 MAPK
signaling and Akt activation1,2,27,28 In particular cell types, irreversible EMT can be
induced by Ras-Raf MAPK signaling alone29, but in human keratinocytes both,
TGFβ and MAPK signaling appear to be required27. In cholesteatoma, we have
demonstrated a significantly increased ERK1/2 MAPK activation but a negligible
activation of the TGFβ pathway. This finding, concomittant with the benign character
of cholesteatoma, argues against irreversible EMT. This may indicate that the EMT
characteristics in cholesteatoma are hallmarks of reversible EMT, which is a well
known phenomenon in wound healing30.
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We therefore postulate that in cholesteatoma, the epithelial cells are subjected to
a wound healing mechanism.
Cholesteatoma stroma
We found an increase in TGFβ and nuclear localization of pSmad2 in cholesteatoma
stromal cells, but not a significant change in expression of the inhibitor Smad7.
Stromal bio activation of TGFβ, however, is enhanced, which is clearly shown by
the excessive deposition of fibronectin EDA. Recently, it has been demonstrated
that in normal skin and in normal scarring fibroblasts, treatment with TGFβ increases
Smad7 expression, whilst in keloid fibroblasts no TGFβ-mediated Smad 7 regulation
was found31. In cholesteatoma stroma, although not increased, Smad7 expression
was found to be correlated to TGFβ and pSmad2,  indicating TGFβ controlled
extracellular matrix deposition.
In healing wounds, FN is present at high levels and derived from two sources:
plasma FN, which lacks the EDA segment and cellular FN, which contains EDA+ FN
and which is synthesized locally in the wound tissue32. At the wound site, the
epithelium must migrate rapidly to cover the injury effectively to prevent deeper
damages. In this process, FN EDA plays an important role because it provides a
supporting scaffold that stimulates migration of epithelial and epidermal cells32.
The FN-EDA presence in cholesteatoma stroma may therefore promote cell
migration.
Evidence has been provided that TGFβ is important in wound healing and
that one of its most important functions is the control of the inflammatory
response33. The dominant role of TGFβ in the immune system is to induce tolerance
as well as to maintain and resolve inflammation34. However, it appears that
inflammation in cholesteatoma stroma is not down-regulated1, but persistent for
several reasons: 1) the cholesteatoma particle can be considered to be a foreign
body, a corpus alienum, which can induce a recurrent inflammatory reaction in
the middle ear35. 2) inflammation is recurrent because in most cholesteatoma,
biofilms that can release endotoxins are present36. 3) inflammation persists because
of lack of clearance in the enclosed cavity of the middle ear.
When inflammation does not cease, different cellular responses may occur. It
has been reported that fibroblasts lose their ability to down regulate some of their
ECM producing activities34. Moreover, with prolonged inflammation, increasing levels
of TGFβ are produced in an attempt to control the inflammatory reaction34. Although
in cholesteatoma stroma, numerous inflammatory cells are present which can
inhibit TGFβ signaling, such as IFNγ and TNFα1, it appears that in cholesteatoma
stroma, this inhibition is subordinate to the signaling potency of TGFβ.
The conclusion of this study is that TGFβ bio-activation in cholesteatoma epithelium
is not augmented, but still correlates to survival and migration. In the stroma,
TGFβ bio-activation leads to excessive ECM deposition. These processes are
symptoms of chronic wound healing, in which the balance between initiation and
decrease of immune response is disturbed. We postulate that other aberrant cellular
processes in cholesteatoma, such as increased angiogenesis and bone erosion
can also be explained within the concept of cholesteatoma as a chronic wound
healing process.
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Summary and General Discussion
To investigate cellular pathways  in human cholesteatoma we made use of
immunohistochemistry. We have chosen this technique for several reasons:
1. Cellular signaling pathways are post transcriptional processes, which means
that the activation of such a pathway is not due to an increase in the
production of a certain protein, but is due to whether or not a certain
protein is activated or deactivated.
2. In cholesteatoma, epithelium and stroma are entangled (Fig. 1), which
makes it virtually impossible to separate e.g., by proteolytic cleavage,
epithelium from stroma and to analyze their different cells by RNA, or DNA
analysis.
3. In skin, the cells from the basal layer have different protein expression
patterns from those in the suprabasal layers and in the stratum corneum.
4. In this study it is essential to investigate at which location different proteins
are present and activated.
In chapter 1, cholesteatoma is described from a general clinical, morphological,
biological and molecular point of view. Briefly, different hypotheses of cholesteatoma
genesis are discussed. Arguments to distinguish cholesteatoma benign character
from a malignancy are considered from different points of view. In this chapter,
features of cholesteatoma wound healing and inflammation processes and the
complexity of its protein signaling are indicated.
A detailed description of the different cellular pathways and proteins investigated
in this thesis is presented in chapter 2. This includes 3 downstream pathways in
MAPkinase signaling-, the pAkt- and TGFb signaling pathways. Moreover, activation
of p53 and its influence on apoptotic processes and the complicated role of p21cip1/
waf1 in cell cycle control is reviewed.
In chapter 3, differences in proliferation, cell cycle arrest and apoptosis between
cholesteatoma and control skin were determined. Our results indicated that in
cholesteatoma epithelium an increased expression of Ki-67, a marker of cell
proliferation, is accompanied by an increase in the p53- as well as the cell cycle
arrest protein p21cip1/waf1. We also demonstrated a significant positive correlation
between p53 and p21cip1/waf1. Apoptosis is very low in the cholesteatoma epithelium.
This was established by the active caspase 3 staining and the TUNEL assay. In
immunohistochemistry it is of the utmost importance to use adequate controls.
This has also turned out to be true for the TUNEL assay, for false positive TUNEL
staining was an important problem to overcome in the first stages of this study. Of
importance is that, in different reports appropriate controls were not used and
pictures with apoptotic cells were not shown, which makes these studies not
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reliable1,2. It is of importance that an apoptotic morphology and a positive apoptotic
staining both must be present to be allowed to call a cell apoptotic, unfortunately,
this is not always the reported3,4.
The results in cholesteatoma epithelium indicate that the increased proliferation is
not compensated by apoptosis, but might be associated with cell cycle arrest.
The results in chapter 4 show that in human cholesteatoma epithelium the Ras/
Raf/ ERK1/2 MAPK pathway is involved in p53-dependent increased expression of
p21cip1/waf1. This was confirmed by the correlated expression of p53 and p21cip1/waf1
and that of p21cip1/waf1 and active ERK1/2. Interestingly, ERK1/2 activation has
been associated with both stimulation and inhibition of cell proliferation. The
magnitude and the duration of ERK1/2 activation determines whether the cellular
response is proliferation or cell cycle arrest. ERK1/2-mediated induction of
proliferation requires a transient, low ERK1/2 activation while induction of p21cip1/
waf1 expression requires a strong and sustained ERK1/2 signaling. In cholesteatoma
epithelium, these differential processes were visualised in the basal and suprabasal
layers. In the basal cell layers, i.e. the proliferating compartment, only pERK1/2
was expressed. In the suprabasal layers, when pERK1/2 expression was sustained,
the cells were also found positive for the cell cycle arrest protein p21cip1/waf1.
Prolonged MAPK-induced cell cycle inhibition causes accumulation of epithelial
cells, which are in G0-arrest5. We concluded therefore that in human cholesteatoma,
prevalent cell cycle arrest might contribute to epithelial hyperplasia.
Alterations in specific signal transduction pathways may explain abnormal
differentiation of the keratinocytes in cholesteatoma.
In chapter 5 the correlation between terminal differentiation and signaling via
the MAPKs has been investigated. We found that the presence of pERK1/2 and
pp38 was positively associated with the expression of involucrin. Activated JNK
expression appeared not to be involved in this process. This indicates that terminal
differentiation in cholesteatoma epithelium proceeds via activation of pERK1/2
and p38 MAPK signaling pathways. Our results were in contrast with previous
articles in which p38 signaling is mentioned to be the most important involucrin
regulatory mechanism in keratinocytes 6. We also could not confirm the finding of
Efimova et al concerning the pp38-related synchronous reduction in ERK1/2
activity7. In this chapter we argued that growth factor receptor activation and
other pro- inflammatory responses may regulate a parallel ERK1/2 and p38 signaling
and subsequent augmented involucrin up regulation. Another reason for
autonomous activation of  ERK1/2 may be an anchorage-independent survival of
cholesteatomal keratinocytes. The cholesteatoma basal membrane has been
demonstrated to be aberrant and disrupted8.  Protection of epithelial cells against
loss of anchorage is associated with and requires sustained ERK1/2 MAPK
phosphorylation9. The assumption that cholesteatoma keratinocytes are subjected
to anchorage-independent survival is in line with our previously demonstrated
sustained active ERK1/2 expression and minimal apoptosis10,11. Remarkably, this
survival mechanism is of importance in tissue repair processing and for migrating
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keratinocytes at the leading edge of a cutaneous wound. The arguments of parallel
signaling due to inflammation- induced cellular stress response or keratinocyte
survival program during wound healing may positively hold true for cholesteatoma
tissue (Efimova, pers comm.)
In chapter 6, the protein expression of pAkt/PKB, was found to be significantly
increased when compared to control skin. This is concomitant with our previous
reports in which we demonstrated minimal apoptosis in cholesteatoma epithelium.
The late terminal differentiation marker filaggrin was found to be significantly
decreased and although PI3K/ Akt signaling has been demonstrated to be involved
in late terminal differentiation, we were not able to establish an association between
pAkt and filaggrin12. We found the terminal differentiation marker involucrin
significantly increased, but we were also not able to establish a correlation between
pAkt and involucrin. In psoriasis , however, the same differentiation profile has
been reported: an augmented involucrin expression and an  absence or reduction
in the amount of filaggrin13,14. It has been suggested that abnormalities of cell
surface adhesion structures might account for the dysregulation of the cornified
envelope components15. This has recently been supported by the report of Calautti,
in which evidence has been provided that differentiation-specific activation of the
PI3K pathway requires the cadherin-catenin adhesion complexes12. Thus, protection
against apoptosis occurs by activated Akt, but initiation of late terminal
differentiation needs an additional component: cell adhesion. In their analysis of
cholesteatoma tissue integrity Naim et al. found, contrary to normal skin, that
beta-catenin was diminished or absent in cholesteatoma suprabasal layers16. This
indicates that, in line with our previous reports, decreased or absent cellular contact
in cholesteatoma epithelilum may be the cause of both increased involucrin and
decreased filaggrin expression.
TGFβ is thought to be a key factor involved in wound healing and the objective of
chapter 7 was to investigate, whether TGFβ is activated in human cholesteatoma.
In the epithelium, we found concordant expressions of TGFβ and p-Smad2,
but a decreased Smad7 expression when compared to its control. The correlations
between TGFβ, pSmad2 and Smad7 may indicate that Smad activation and inhibition
are still operational. Nevertheless, in spite of the decreased Smad7 expression
these processes do not lead to a significant pSmad2 up regulation. It has been
reported that besides inhibiting Smad2 activation, Smad7 appears to play a critical
role in mediating apoptosis by activation of the JNK signaling pathway. The
decreased Smad7- and our previously demonstrated decreased JNK expression in
cholesteatoma epithelium may therefore represent protection against apoptosis.
In this chapter we also compared, in a pilot study, the results of this study with
the results of our study of MAPkinase signalling,  and we found correlations between
TGFβ, pSmad2 and pERK1/2 (p=0.02 and 0.03). We hypothesized that in
cholesteatoma epithelium default levels of TGFβ may become effective because of
co-operative signaling, leading to augmented transcription of different genes. One
of these genes may be p21cip1/waf1, which we previously found to be increased and
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related to pERK1/2 expression10. This may be a mechanism of fine-tuning of TGFβ
signaling, which indicates that protein signaling may be augmented, but not out
of control.
In cholesteatoma stroma, TGFβ and pSmad2 were increased, while Smad7
expression was equal when compared to control skin. EDA-FN accumulation in
cholesteatoma stroma was excessive whereas no EDA-FN expression was not
detectable in control skin. In this chapter it is argued that the increased TGFβ,
pSmad2 and EDA fibronectin expressions may be cellular responses to persistent
inflammation. There may be several reasons for such a hypothesis: 1) the
cholesteatoma particle can be considered to be a foreign body, a corpus alienum,
which can induce a recurrent inflammatory reaction in the middle ear17. 2)
inflammation is recurrent because in most cholesteatoma, biofilms are present
which can release endotoxins18. Endotoxins can reinitiate inflammation because
they can trigger many cells to produce cytokines. 3) inflammation will be self
perpetuating because of lack of clearance in the enclosed cavity of the middle ear.
There may also be a combination of these factors, or all may play a role in
cholesteatoma chronicity.  In this chapter we indicate that cholesteatoma is a
process of chronic wound healing in which TGFβ signaling and a persistent
inflammation appears to be contributing factors to its chronicity.
General Discussion
In cholesteatoma epithelium, increased expressions of those proteins were found,
which are involved in proliferation (Ki-67), cell cycle arrest (p53 and p21cip1/waf1),
early expression of the terminal differentiation protein involucrin and survival (pAkt).
Moreover, increased activation of MAPK- and its association with TGFβ cellular
signaling cascades were demonstrated. The proteins of which the expressions
were decreased were those concerning late terminal differentiation (filaggrin) and
apoptosis (active caspase 3). We found different correlations between the various
investigated proteins. We therefore assume that these correlations can be placed
in the context of interconnected signaling processes.  It appears that these
connections in both MAPK- and TGFβ signaling, support cell cycle arrest, early
terminal differentiation and survival (Fig.1) which are hallmarks of wound healing.
This suggests that cholesteatoma epithelium behaves like a wound healing process
in which the keratinocytes are migrative. Many biological characteristics of
cholesteatoma epithelial cells can be explained with this concept. Increased
proliferation, which is shown by the increased Ki-67 proportion in cholesteatoma
epithelium, is not compensated by increased apoptosis. This can explain
hyperplasia, which is a common phenomenon in cholesteatoma. Hypertrophy is
also frequently present and may be caused by cell cycle arrest but also by
differentiation, for it has been demonstrated that these two processes are known
to induce cellular volume19,20. Moreover, it has been reported that keratinocytes in
a wound healing process are hypertrophic, (which is also due to cell cycle arrest
and aberrant differentiation)21. Aberrant differentiation, the early and increased
expression of involucrin, but also the decrease in filaggrin expression may be due
to loss of adhesion12,15. This loss of adhesion may be caused by an interrupted and
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altered basal membrane and/or a decreased α catenin expression, which previously
have been reported in cholesteatoma epithelium8,16. Moreover, this lack of adhesion
is visible, because in different reports cholesteatoma pictures reveal a widening of
intercellular space, the latter is also reported to be a phenomenon in wound
healing21. The decrease of filaggrin can also explain another biological characteristic
of cholesteatoma epithelium: that of parakeratosis. When late terminal
differentiation is not initiated, the cells will retain their nuclei and the tissue becomes
parakeratotic. Interestingly, early terminal differentiation, demonstrated by
increased involucrin expression will not cease proliferation, for involucrin-positive
cells are still capable to continue DNA synthesis19.
The increased TGFβ and pSmad2 expressions in cholesteatoma stroma and the
increased EDA-Fibronectin also point to a chronic wound healing process. In
cholesteatoma, this process is clearly visible by the accumulation of EDA-fibronectin.
Although it is chronic in cholesteatoma, we suppose that it is still part of a normal
process of wound healing for EDA-fibronectin is essential in appropriate self limited
wound healing22. Moreover, in normal wound healing, the final signal is that of the
disappearance of inflammatory cells. It has been reported that this occurs by
apoptosis. In chapter 3, although there was minimal apoptosis in cholesteatoma
epithelium, we found many apoptotic cells in the stroma. Cholesteatoma recurrence
can also be explained, for it has been reported that, after injury, cells can be
reactivated even years after the first event23.
In conclusion, we hypothesize that in cholesteatoma cellular signaling occurs along
the lines of normal, but chronic, wound healing.
Figure 1. The pathways investigated in this thesis. The red lines represent significant correlations.
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Further research
We recommend research into pharmacological interventions aimed at control of
inflammation. Because application of antibiotics has proven to be not very successful
probably because of the presence of biofilms- we believe that anti microbial peptides
may be an adequate novel therapy.
To get more insight in cholesteatoma genesis we suggest to study the influence of
external stimuli, such as keratin particles and endotoxins, on the protein expression
and protein signaling profile in the advancing front of meatal epidermis and middle
ear epithelium.
Retraction pockets are considered to be a pre-stage in cholesteatoma formation,
although the development to a cholesteatoma is tentative. Of interest is therefore
to compare the protein expression and protein signaling profile of retraction pocket
tissue to that of cholesteatoma.
We further recommend to study whether biofilms play a role in cholesteatoma
development and progress. This should be done by detection of both, bacterial
colonies and their glycocalix layer, in retraction pockets and different types of
cholesteatoma.
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In vergelijking met modern onderzoek zoals gen expressie profiling lijkt deze stu-
die, die zich alleen richt op de expressie van eiwitten, tamelijk beperkt. Met be-
trekking tot het cholesteatoom zijn er echter sterke argumenten om de expressie
van bepaalde eiwitten te onderzoeken. Cellulaire signalerings routes zijn activerings
processen, die de cel motiveren tot een serie van reacties op een bepaalde toe-
stand in of buiten de cel, bijvoorbeeld als er sprake is van cellulaire stress. Een
dergelijke signalering is posttranscriptioneel, wat betekent dat activatie van een
signaal niet het gevolg is van een toename van een bepaald eiwit, dus na transcriptie
van het DNA, maar door het feit of een bepaald eiwit wel of niet geactiveerd is.
Bovendien zijn in het cholesteatoom het epitheel en het stroma zodanig met el-
kaar verstrengeld (Hoofdstuk 7, fig. 1) dat het onmogelijk is om, bijvoorbeeld met
eiwitsplitsende enzymen, het epitheel van het stroma te scheiden om met behulp
van moleculaire technieken de verschillende cellen ervan te onderzoeken. Daar-
naast, in de huid, hebben de cellen van de basale laag een ander eiwit expressie
profiel dan de cellen in de suprabasale lagen en in de stratum corneum. Het
onderzoek naar de aanwezigheid van verschillende eiwitten en de activatie daar-
van in cellen in bepaalde huidlagen is daarom van belang in deze studie.
In hoofdstuk 1 wordt het cholesteatoom beschreven vanuit een klinisch, morfo-
logisch, biologisch en moleculair gezichtspunt. Verschillende theorieën met be-
trekking tot het ontstaan van het cholesteatoom worden besproken. Op grond
van verschillende argumenten wordt onderscheid gemaakt tussen de benigne
(goedaardige) kenmerken van het cholesteatoom en die van een maligniteit
(kwaadaardige tumor). In dit hoofdstuk worden de kenmerken van wondgenezing
en ontsteking in het cholesteatoom, en de hieruit volgende complexiteit van de
eiwit signalering aangegeven.
In hoofdstuk 2 wordt een gedetailleerde beschrijving gepresenteerd van de ver-
schillende cellulaire signalerings routes en eiwitten, die onderzocht zijn in dit proef-
schrift. Deze routes, van celmembraan naar –kern, zijn de drie MAPKinases-, de
pAkt- en de TGFβ signalerings routes. Bovendien wordt uiteengezet hoe p53 ge-
activeerd kan worden, wat de invloed van p53 is op apoptotische processen en
wat de gecompliceerde rol is van p21cip1/waf1 met betrekking tot de cel cyclus.
In hoofdstuk 3, zijn de verschillen in de mate van proliferatie, cel cyclus arrest
en apoptose tussen cholesteatoom en controle huid vastgesteld. Onze resultaten
laten zien, dat in het epitheel van het cholesteatoom Ki-67 verhoogd aanwezig is
en dat dit vergezeld wordt van een toename van zowel p53 als van het cel cyclus
arrest eiwit p21cip1/waf1. Wij toonden ook een significant positieve correlatie aan
tussen p53 en p21cip1/waf1. Er was minimaal apoptose in het epitheel van het
cholesteatoom. Dit werd aangetoond door de actief Caspase 3 kleuring en de
TUNEL test. Het is van buitengewoon belang in de immunohistochemie om de
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juiste controles te gebruiken. Dit is maar al te waar gebleken met betrekking tot
de TUNEL test, want de vals-positieve TUNEL kleuring was een belangrijk  pro-
bleem dat in het begin van dit onderzoek opgelost moest worden. Het is veelbete-
kenend, dat in verschillende publicaties geen controles zijn gebruikt en/ of dat
foto’s van apoptotische cellen niet getoond worden, zodat deze studies niet be-
trouwbaar genoemd kunnen worden1,2. Het is van belang te onderkennen, dat
zowel een apoptotische morfologie als een positieve apoptotische kleuring aan-
wezig moeten zijn om een cel apoptotisch te kunnen noemen, dit is helaas niet
altijd het geval3,4. De resultaten van het onderzoek van het epitheel van het
cholesteatoom geven aan, dat de verhoogde proliferatie niet gecompenseerd wordt
door apoptose maar zou kunnen samengaan met cel cyclus arrest.
De resultaten van hoofdstuk 4 laten zien, dat in cholesteatoom epitheel de Ras/
Raf/ ERK1/2 MAPKinase signalerings route betrokken is bij de p53-afhankelijke
toename van p21cip1/waf1 expressie. Dit werd bevestigd door de gecorreleerde ex-
pressie van p53 en p21cip1/waf1 en die van p21cip1/waf1 en geactiveerde ERK1/2. Inte-
ressant is dat activatie van ERK1/2 geassocieerd wordt met zowel stimulatie als
met remming van cel proliferatie. De sterkte en de duur van de ERK1/2 activatie
bepaalt het antwoord van de cel: proliferatie of cel cyclus arrest. De door ERK1/2
bewerkstelligde opregulatie van proliferatie vereist een tijdelijk, laag ERK1/2
activeringssignaal, terwijl opregulatie van p21cip1/waf1 een sterk en langdurig ERK1/
2 activeringssignaal vereist. In het epitheel van het cholesteatoom zijn deze ver-
schillende processen zichtbaar door de enkelvoudige ERK1/2 expressie in het
proliferatieve compartiment. In de suprabasale lagen, waar langdurige ERK1/2
expressie aanwezig is, zijn de cellen ook positief bevonden voor het cel cyclus
arrest eiwit p21cip1/waf1. Aanhoudende remming van de cel cyclus veroorzaakt sta-
peling van epitheliale cellen die in G0-arrest zijn5. Wij concluderen daarom, dat in
het cholesteatoom overheersende cel cyclus arrest zou kunnen bijdragen aan
epitheliale hyperplasie.
Veranderingen in specifieke signaleringsroutes zouden de abnormale terminale
differentiatie kunnen verklaren van de keratinocyten in het cholesteatoom.
In hoofdstuk 5 is de correlatie onderzocht tussen terminale differentiatie en
signalering via de MAPKs. In dit hoofdstuk is aangetoond dat de aanwezigheid van
geactiveerd ERK1/2 en –p38 positief geassocieerd is met de expressie van
involucrine. Geactiveerd JNK lijkt niet betrokken te zijn bij dit proces. Dit geeft
aan, dat terminale differentiatie in het epitheel van het cholesteatoom geschiedt
via activatie van ERK1/2 en p38 signaleringsroutes. Onze resultaten zijn in tegen-
spraak met eerdere publicaties waarin p38 signalering het belangrijkste regule-
rend mechanisme wordt genoemd6. Wij konden ook niet de bevinding van Efimova
bevestigen met betrekking tot de p38-gerelateerde reductie van ERK1/2 activi-
teit7. In dit hoofdstuk wordt beargumenteerd dat groeifactor receptor activatie en
andere pro-inflammatoire responsen een parallelle  ERK1/2 and p38 signalering
teweeg zou kunnen brengen. Een andere reden voor autonome ERK1/2 activatie
zou kunnen zijn dat keratinocyten in het cholesteatoom onderworpen zijn aan een
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overlevingsprogramma veroorzaakt door verminderde cel-matrix hechting. Het is
aangetoond, dat de basaal membraan van het cholesteatoom afwijkend en on-
derbroken is8. Bescherming van cellen tegen apoptose door verminderde cel-ma-
trix binding is geassocieerd met, en vereist een langdurige ERK1/2 MAPK activatie9.
De aanname dat cholesteatoom keratinocyten onderworpen zijn aan een derge-
lijke hechtings-onafhankelijke overleving is in overeenstemming met onze eerder
aangetoonde langdurige ERK1/2 activatie en minimale apoptose10,11. Het opmer-
kelijke is dat dit overlevingsmechanisme van belang is bij de voortgang van weefsel-
herstel en, in de huid, voor de migrerende keratinocyten aan de frontlinie van de
wond. De argumenten van een parallele signalering ten gevolge van een door
inflammatie geinduceerde stress respons of van een keratinocyten-
overlevingsprogramma gedurende wondgenezing kunnen met betrekking tot het
cholesteatoomweefsel zeker waar zijn (persoonlijke communicatie met Efimova).
De bevinding in hoofdstuk 6 was dat het overlevingseiwit pAkt/PKB significant
verhoogd is ten opzichte van controle huid. Deze waarneming valt samen met de
resultaten uit eigen eerdere publikaties waarin minimale apoptose is aangetoond
in het epitheel van het cholesteatoom. Het eiwit dat betrokken is bij late terminale
differentiatie, filaggrine, werd significant verlaagd aangetroffen en hoewel aange-
toond is dat PI3K/Akt signalering betrokken is bij terminale differentiatie, konden
wij geen associatie aantonen tussen pAkt en filaggrine12. Involucrine, dat even-
eens betrokken is bij terminale differentiatie, was significant verhoogd, maar ook
tussen pAkt en involucrine konden we niet een relatie aantonen. In psoriasis ech-
ter, is melding gemaakt van eenzelfde differentiatie profiel: een verhoogde
involucrine expressie en een afwezigheid of verlaging van de hoeveelheid
filaggrine13,14. Er is gesuggereerd dat abnormale structuren van adhesiemoleculen
verantwoordelijk zouden kunnen zijn voor de ontregeling in productie van de com-
ponenten van de cornified envelope15. Deze suggestie is onlangs ondersteund
door een artikel van Calautti, waarin bewezen werd dat de cadherine-catenine
adhesie complexen nodig zijn om tot een differentiatie-specifieke activatie van
PI3K te komen12. Kortom, bescherming tegen apoptose geschiedt door middel
van geactiveerde Akt, maar voor de aanzet tot late differentiatie is nog een an-
dere component nodig: cel adhesie. Bij de analyse van de integriteit van
cholesteatoom weefsel vonden Naim et al. dat, in tegenstelling tot normale huid,
beta-catenine verminderd dan wel afwezig was in de suprabasale lagen van het
cholesteatoom16. Dit impliceert dat, in overeenstemming met onze eerdere
publicaties, verminderd of afwezig cellulair contact in cholesteatoom epitheel de
oorzaak kan zijn van zowel verhoogde involucrine als van een verlaagde filaggrine
expressie.
Van TGFβ wordt aangenomen dat het een spilfunctie inneemt bij wond genezing
en de onderzoeksvraag van hoofdstuk 7 was of in het cholesteatoom, de TGFβ
signalerings route is geactiveerd.
In de epithelia van cholesteatoom en huid vonden we overeenkomstige
expressies van TGFβ en geactiveerd Smad2 (pSmad2), maar in het cholesteatoom
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was de expressie van de antagonist Smad 7 verlaagd ten opzichte van normale
huid. De correlaties tussen TGFβ, pSmad2 en Smad7 zijn een indicatie dat Smad
activatie en remming beide operationeel zijn. Desalnietemin, ondanks de ver-
laagde Smad7 expressie leiden deze processen niet tot een significante toename
van pSmad2. Het is vermeld dat behalve de remming van Smad2 activatie, Smad7
een belangrijke rol lijkt te spelen bij het bewerkstelligen van apoptose door activatie
van de JNK signalerings route. De verlaagde Smad7- en onze eerder aangetoonde
niet verhoogde JNK expressie in cholesteatoom epitheel zou daarom kunnen dui-
den op bescherming tegen apoptose. In dit hoofdstuk vergelijken we in een pilot
studie de resultaten van deze studie met die van de resultaten van ons onderzoek
naar de MAPKinase signalerings route en we hebben correlaties gevonden tussen
TGFβ, pSmad2 en pERK1/2 (p=0.02 and 0.03). Wij veronderstellen dat in het
epitheel van het cholesteatoom, een standaard niveau van TGFβ effectief kan
worden door samenwerking met andere signalerings routes, en dat dit weer kan
leiden tot verhoogde transcriptie van verschillende genen. Een van deze genen
zou p21cip1/waf1 kunnen zijn, dat we eerder al verhoogd aanwezig hebben gevonden
en dat bovendien gerelateerd is aan ERK1/2 expressie10. Dit kan een fijn regulerings
mechanisme zijn van de TGFβ signalering, wat aangeeft dat eiwit signalering ver-
hoogd kan zijn, maar sterk gecontroleerd.
In het stroma van het cholesteatoom zijn TGFβ and pSmad2 verhoogd,
terwijl de Smad7 expressie gelijk was aan die in controle huid. EDA-fibronectine
(EDA-FN) accumulatie in het stroma van het cholesteatoom was excessief, terwijl
er geen EDA-FN aantoonbaar was in controle huid. In dit hoofdstuk wordt
beargumenteerd dat de verhoogde stromale expressies van TGFβ, pSmad2 en
EDA-FN, het cellulaire antwoord is op een langdurige ontsteking. Er zijn verschil-
lende redenen voor een dergelijke hypothese:1) het cholesteatoom kan worden
beschouwd als een “vreemd lichaam”, dat in het middenoor een steeds terugke-
rende (=chronische) ontstekingsreactie kan veroorzaken17. 2) De inflammatie is
chronisch omdat in de meeste cholesteatomen biofilms aanwezig zijn die
endotoxinen en bacteriën kunnen vrijmaken18. Evenals bacteriën kunnen
endotoxinen opnieuw de ontsteking initiëren door de cellen aan te zetten tot de
productie van cytokinen. 3) inflammatie kan zichzelf consolideren door het gebrek
aan clearance in de omsloten ruimte van het midden oor. Er kan ook een combina-
tie mogelijk zijn van deze drie factoren, of ze zouden allemaal een rol kunnen
spelen in de chroniciteit van het cholesteatoom. In dit hoofdstuk geven we aan,
dat het cholesteatoom een proces is van chronische wondgenezing, waaraan de
TGFβ signalerings route en de voortdurende ontsteking lijken bij te dragen
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In het epitheel van het cholesteatoom zijn verhoogde expressies gevon-
den van eiwitten die betrokken zijn bij proliferatie (Ki-67), cel cyclus arrest (p53
en p21cip1/waf1 ), voortijdige terminale differentiatie (involucrine) en overleving (pAkt).
Bovendien is aangetoond dat de activatie van MAPK- verhoogd is en geassocieerd
is met de TGFβ signalerings route. De eiwitten waarvan de expressie verlaagd
was, hebben betrekking op late terminale differentiatie (filaggrine) en apoptose
(actief Caspase3). We hebben verschillende correlaties gevonden tussen de ver-
schillende eiwitten die onderzocht zijn. We veronderstellen, dat deze correlaties
binnen de context passen van samenhangende signalerings processen. Het lijkt
dat deze connecties in zowel de MAPK- als de TGFβ signalering, cel cyclus arrest,
vroege terminale differentiatie en overleving ondersteunen, wat kenmerkend is
voor wondgenezing. Samenvattend suggereert dit, dat het epitheel van het
cholesteatoom zich gedraagt als een wond genezingsproces met migrerende
keratinocyten. Veel biologische karakteristieken van het epitheel van het
cholesteatoom kunnen verklaard worden met behulp van dit concept. Verhoogde
proliferatie, aangetoond door de proportioneel verhoogde Ki-67, wordt niet ge-
compenseerd door verhoogde apoptose. Dit kan hyperplasie verklaren, wat een
normaal fenomeen is in het cholesteatoom. Hypertrofie is ook frequent aanwezig
en kan veroorzaakt worden door cel cyclus arrest, maar ook door differentiatie,
omdat deze twee processen het cellulair volume doen toenemen19,20. Bovendien is
het aangetoond dat keratinocyten in een wondgenezingsproces hypertroof zijn
(wat derhalve een gevolg is van cel cyclus arrest en afwijkende differentiatie)21.
Afwijkende differentiatie, door de voortijdige expressie van involucrine maar ook
door de vermindering van filaggrine, kan veroorzaakt worden door verlies van
adhesie12,15. Dit verlies van adhesie kan veroorzaakt zijn door een onderbroken en
veranderde basaal membraan en/of een verminderde α catenine expressie. Beide
verschijnselen zijn eerder aangetoond in het epitheel van het cholesteatoom8,16.
Bovendien is het gebrek aan adhesie zichtbaar omdat in verschillende publikaties
op foto’s van een cholesteatoom een verwijding van de intercellulaire ruimtes te
zien is, dit laatste is ook vermeld als een fenomeen in wond genezing21. De af-
name van filaggrine kan ook een ander biologisch kenmerk van het epitheel van
het cholesteatoom verklaren: dat van parakeratose. Als de late terminale diffe-
rentiatie niet opgestart wordt, behouden de cellen hun kernen en wordt het weef-
sel parakeratotisch. Interessant is dat vroege terminale differentiatie, zoals aan-
getoond door involucrine expressie, de proliferatie niet doet stoppen, want
involucrine-positieve cellen zijn nog in staat om DNA te synthethiseren19. De toe-
name van TGFβ en pSmad2 in het stroma van cholesteatoom en de verhoogde
EDA-fibronectine duiden ook op een chronisch wondgenezingsproces. In het
cholesteatoom is dit proces duidelijk zichtbaar door de accumulatie van EDA-
fibronectine. Hoewel chronisch, nemen we aan, dat dit toch een onderdeel is van
normale wondgenezing want EDA-fibronectine is noodzakelijk voor normale, zelf-
beperkende wondgenezing22. Bovendien, bij normale wondgenezing is het laatste
signaal dat van de verdwijning van de ontstekingscellen. Het is vermeld dat dit
gebeurt door middel van apoptose23. In hoofdstuk 3, hoewel er minimaal apoptose
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was in het epitheel, vonden we vele apoptotische cellen in het stroma. De recurrency
van het cholesteatoom kan ook worden verklaard, want cellen kunnen, zelfs vele
jaren na verwonding, opnieuw geactiveerd worden24.
Samenvattend, in het cholesteatoom lijkt cellulaire signalering te verlopen langs
de lijnen van normale, maar chronische wondgenezing.
Toekomstig onderzoek.
Wij adviseren onderzoek te verrichten naar farmacologische interventies gericht
op ontstekings controle. Omdat de toediening van antibiotica niet erg succesvol is
gebleken- waarschijnlijk wegens de aanwezigheid van biofilms- denken wij dat
het gebruik van antimicrobiële peptiden een geschikte nieuwe therapie zou kun-
nen zijn.
Om meer inzicht te verwerven in het ontstaan van het cholesteatoom stellen wij
voor om de invloed van externe stimuli, zoals keratine deeltjes en endotoxinen,
op de eiwitexpressie en het eiwitsignaal profiel te bestuderen in het advancing
front van huid uit de buitenste gehoorgang en midden oorslijmvlies25.
Retractiepockets worden beschouwd als een voorstadium van cholesteatoom vor-
ming, hoewel de daadwerkelijke ontwikkeling tot een cholesteatoom niet te voor-
spellen is. Het is daarom van belang om de eiwitexpressie en het eiwit
signaleringsprofiel van retractiepocket weefsel te vergelijken met dat van
cholesteatoom. Wij doen daarnaast nog de aanbeveling om te bestuderen in hoe-
verre biofilms een rol spelen in de ontwikkeling en voortgang van het cholesteatoom.
Dit zou gedaan kunnen worden door middel van de detectie van zowel bacterie-
kolonies als van hun glycocalix laag in retractiepockets en in verschillende soorten
cholesteatoom.
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Abbreviations
Akt AKT8 virus oncogene cellular homolog
Apaf-1 Apoptotic protease activating factor
APO1 apoptosis-related protein
ARF Alternative reading frame
ASK1 Apoptosis signal-regulating kinase 1
AP1 Activator protein 1
BAD Bcl2-antagonist of cell death
Bcl-2 B-cell lymphomal leukaemia-2
Bcl-XL B-cell lymphomal leukaemia-XL
BMP Bone morphogenetic proteins
CAD Caspase-activated DNAse
CAK Cyclin activating kinase
cAMP Cyclic adenosin monophosphate
Caspase Cysteine proteases with aspartate specifity




CREB cAMP response element-binding protein
Crk CT10 sarcoma oncogene cellular homolog
DAB Diaminebenzidinetetrahydrochloride
DNA Desoxyribo nucleic acid
DR Death receptor
E2F early-region-2 transcription-factor-
ECM Extra cellular matrix
EGF Epidermal growth factor
Erk Extracellular signal-regulated kinase
FADD Fas-associated protein with death domain
FAK Focal adhesion kinase
FEN1 Flap endonuclease 1
FH Forkhead
GADD45 Growth arrest and DNA damage protein 45
GSK3 Glycogen synthase 3
GRB2 Growth factor receptor-bound protein
GTP Guanine nucleotide tri phosphate
IGF Insulin-like growth factor
IkB Inhibitor of NFκB
IKK IkappaB kinase
ILK Integrin-linked kinase
JNK c-Jun N-terminal kinase
KILLER Killer Cell Immunoglobulin-Like Receptor
LPS Lipopolysaccharide
MAPK Mitogen-activated protein kinase
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MAPKAP MAP kinase activated protein kinase
MDM2 Murine double minute 2
MEK MAPK/Erk kinase
MEKK MAPK/Erk kinase kinase
NF-κB Nuclear factor kappa B
NIK NF-κB inducing kinase
PCAF p300/CBP-associated factor
PCNA proliferating cell nuclear antigen
PdGF Platelet-derived growth factor
PDK1 Phosphoinositide dependent kanse-1
PI3K Phosphoinositide 3 kinase
PIP2 Phosphatidylinositol 3,4-biphosphate
PIP3 Phosphatidylinositol 3,4,5-triphosphate
PKA Protein kinase A
PKB Protein kinase B
PKC Protein kinase C
PPAR Peroxisome proliferator-activated receptor
PTEN Phosphatase and tensin homologue
PUMA p53 upregulated modulator of apoptosis
RasGRP Ras guanyl nucleotide-releasing protein
Rb Retinoblastoma protein
Rel Reticuloendotheliosis oncogene cellular homolog
SAPK Stress-activated protein kinase
SARA Smad anchor for receptor activation
Shc SH2-containing collagen-related proteins
Smad contraction of Sma and Mad (Mothers against decapentaplegic)
Smurf Smad ubiquitination regulatory factor
SOCS Suppressor of cytokine signaling
SOS Son of sevenless guanine nucleotide exchange factor
SOX Sry-box transcription factors
Src Rous sarcoma oncogene cellular homolog
TAK1 Transforming growth factor-β (TGF-β)-activated kinase 1
TAB TAK-binding protein
TBS Tris-buffered saline
TGFβ Transforming growth factor beta
Thr Threonine
TNFα Tumor necrosis factor alpha
TPA 12-o-tetradecanoylophorbol-13-acetate
TRADD TNF receptor-1-associated death domain protein
TRAF TNF-receptor-associated factor
TRAIL TNF-related apoptosis-inducing ligand
WAF1 Wild-type p53-activated fragment
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